Amedeo Smart

Free Medical Literature Service

 

Amedeo

Parkinson's Disease
  Free Subscription

Articles published in
Mov Disord
    March 2026
  1. FOLKE J, DellaValle B, Jorgensen ML, Mogensen PB, et al
    Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy.
    Mov Disord. 2026 Mar 19. doi: 10.1002/mds.70274.
    >> Share

  2. HELY M
    The Sydney Multicenter Study of Parkinson's Disease: The Why, the How, and the Outcome.
    Mov Disord. 2026 Mar 17. doi: 10.1002/mds.70245.
    >> Share

  3. SALARI M, Etemadifar M, Soleimani S
    Parkinson's Disease in Times of War: Gaps in Knowledge and Emerging Controversies.
    Mov Disord. 2026 Mar 17. doi: 10.1002/mds.70272.
    >> Share

  4. FULLER RLM, Monje MHG, Chahine LM, Delgado EC, et al
    International Parkinson and Movement Disorder Society Clinical Outcome Assessments are Available in REDCap.
    Mov Disord. 2026 Mar 16. doi: 10.1002/mds.70224.
    >> Share

  5. DING H, Xie K, Bange M, Kuhne H, et al
    Macroscale Gradient-Informed Neural Oscillation Topography in Parkinson's Disease.
    Mov Disord. 2026 Mar 16. doi: 10.1002/mds.70277.
    >> Share

  6. HAMMER LH, Cernera S, Oehrn CR, Yao J, et al
    Stimulation and Medication Effects on Subthalamic Nucleus Beta-Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation.
    Mov Disord. 2026 Mar 11. doi: 10.1002/mds.70261.
    >> Share

  7. STEP K, Hernandez CF, Khani M, Eltaraifee E, et al
    Genome-Wide Assessment Reveals Ancestral Differences in Homozygosity Patterns Potentially Linked to Parkinson's Disease Etiology.
    Mov Disord. 2026 Mar 11. doi: 10.1002/mds.70182.
    >> Share

  8. ISIK FI, Pickford R, Chua M, Lewis SJG, et al
    Elevation of Stearoyl-Coenzyme A Desaturase and Monounsaturated Fatty Acids in Parkinson's Disease Serum.
    Mov Disord. 2026 Mar 10. doi: 10.1002/mds.70264.
    >> Share

  9. CORRAL I, Martinez Castrillo JC, Bhatia KP, Garcia Ruiz PJ, et al
    A Pioneering 1915 Film on Movement Disorders in Spain: Parkinsonism, Huntington's Disease, and Paradoxical Kinesia.
    Mov Disord. 2026 Mar 7. doi: 10.1002/mds.70257.
    >> Share

  10. KOUCHACHE T, Zolfaghari S, Bouhadoun S, Delva A, et al
    Reply to Comment on "Delayed Disease Onset Report in UK Biobank: Implications for Prodromal Studies in Parkinson's Disease".
    Mov Disord. 2026 Mar 6. doi: 10.1002/mds.70255.
    >> Share

  11. SCHALKAMP AK, Peall KJ, Harrison NA, Sandor C, et al
    Comment on "Delayed Disease Onset Report in UK Biobank: Implications for Prodromal Studies in Parkinson's Disease".
    Mov Disord. 2026 Mar 5. doi: 10.1002/mds.70253.
    >> Share

  12. GABRIEL ED, Eisinger RS, Lee JM, Hamimi S, et al
    When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions.
    Mov Disord. 2026 Mar 4. doi: 10.1002/mds.70258.
    >> Share

  13. COLE-HUNTER T, Antic S, Lim YH, Zhang J, et al
    Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.
    Mov Disord. 2026 Mar 2. doi: 10.1002/mds.70234.
    >> Share

    February 2026
  14. TIAN Y, Matar E, Berkovsky S, Lewis SJG, et al
    Aberrant Beta-Band Network Alteration Preceding Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2026 Feb 27. doi: 10.1002/mds.70230.
    >> Share

  15. TOFFOLI M, Menozzi E, Chowdhury K, Foltynie T, et al
    Ambroxol for Parkinson's Disease.
    Mov Disord. 2026 Feb 24. doi: 10.1002/mds.70242.
    >> Share

  16. PAPAGIANNAKIS N, Koros C, Simitsi AM, Stefanis L, et al
    Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study.
    Mov Disord. 2026 Feb 23. doi: 10.1002/mds.70236.
    >> Share

  17. ZHANG Y, Chen Y, Kang Y, Chen X, et al
    Novel Variants in DCTN1 Associated with Perry Disease: A Case Series from a Chinese Parkinsonism Cohort.
    Mov Disord. 2026 Feb 22. doi: 10.1002/mds.70244.
    >> Share

  18. XU T, Yu Y, Deng Z, Li L, et al
    Cortical Morphometric Similarity Network Gradient in Parkinson's Disease and its Association with Gene Expression Profiles.
    Mov Disord. 2026 Feb 20. doi: 10.1002/mds.70233.
    >> Share

  19. PISANI S, Vasa F, Velayudhan L, Bhattacharyya S, et al
    Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain.
    Mov Disord. 2026 Feb 20. doi: 10.1002/mds.70222.
    >> Share

  20. OKUBADEJO NU, Schaeffer E, Noyce AJ, Heinzel S, et al
    Addressing Gaps in Parkinson's Disease Etiology: The Need for a Polyexposure Score.
    Mov Disord. 2026 Feb 17. doi: 10.1002/mds.70231.
    >> Share

  21. JAAKKOLA E, Koponen M, Kaasinen V, Hietala J, et al
    Reply to: "Comments on: "Bipolar Disorder as a Long-Term Risk Factor for Parkinson's Disease: A Nationwide Case-Control Study"".
    Mov Disord. 2026 Feb 16. doi: 10.1002/mds.70215.
    >> Share

  22. XIANG N, Cai L, Gao H, Li W, et al
    Comments on: "Bipolar Disorder as a LongTerm Risk Factor for Parkinson's Disease: A Nationwide Case-Control Study".
    Mov Disord. 2026 Feb 16. doi: 10.1002/mds.70214.
    >> Share

  23. GU SC, Sun QY, Zhang W, Shen CY, et al
    Cell-Type-Specific Causal Inference Unveils Novel Targets for Parkinson's Disease.
    Mov Disord. 2026 Feb 13. doi: 10.1002/mds.70223.
    >> Share

  24. LAMOS M, Zackova A, Ulcak D, Gurka B, et al
    Local Field Aperiodic Spectral Power Modulated by Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2026 Feb 13. doi: 10.1002/mds.70232.
    >> Share

  25. CARRILLO M, Hernandez-Pinedo N, Zaldivar-Diez J, Perez-Santos I, et al
    Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkey Model of Parkinson's Disease.
    Mov Disord. 2026 Feb 12. doi: 10.1002/mds.70209.
    >> Share

  26. BARMPA K, Saraiva C, Zagare A, Tuzza M, et al
    Parkinson's Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation.
    Mov Disord. 2026 Feb 11. doi: 10.1002/mds.70176.
    >> Share

  27. NEILSON LE, Lin C, Mishra A, Scott GD, et al
    Small Strokes, Big Impact: Excessive Mortality After Acute Ischemic Stroke in Parkinson's Disease.
    Mov Disord. 2026 Feb 9. doi: 10.1002/mds.70218.
    >> Share

  28. DARDOV VJ, Vasanthakumar A, Kulkarni A, Sundararaman N, et al
    Accelerating Medicines Partnership(R) Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research.
    Mov Disord. 2026 Feb 5. doi: 10.1002/mds.70183.
    >> Share

  29. KOFOED RH, Hvingelby VS, Pineda-Pardo JA, Blesa J, et al
    Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.
    Mov Disord. 2026 Feb 3. doi: 10.1002/mds.70156.
    >> Share

  30. PAINOUS C, Fernandez M, Camara A, Alba-Arbalat S, et al
    Barcelona Progressive Supranuclear Palsy (PSP) Registry: Clinical, Oculomotor, and Cerebrospinal Fluid Markers; from Suggestive to Definite Cases.
    Mov Disord. 2026;41:500-508.
    >> Share

  31. POZZI R, De Sciscio M, Bosetti M, Cano-Crespo S, et al
    Glucocerebrosidase Target Engagement and Therapeutic Plasma and Cerebrospinal Fluid Levels After GT-02287 Administration in Healthy Volunteers.
    Mov Disord. 2026;41:522-527.
    >> Share

    January 2026
  32. NIEMI KJ, Kaasinen V, Weil RS, Joutsa J, et al
    Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease.
    Mov Disord. 2026 Jan 30. doi: 10.1002/mds.70199.
    >> Share

  33. RAJAI FIROUZABADI S, Mohammadi I, Golsorkh H, Mahdavi S, et al
    Hearing Loss in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2026 Jan 30. doi: 10.1002/mds.70206.
    >> Share

  34. DUONG MT, Das SR, Khandelwal P, Vizcarra JA, et al
    Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by alpha-Synuclein Status in Sporadic and Genetic Parkinson's Disease.
    Mov Disord. 2026 Jan 28. doi: 10.1002/mds.70186.
    >> Share

  35. BROOKER SM, Pasquini J, Choi SH, Lafontant DE, et al
    Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay.
    Mov Disord. 2026 Jan 28. doi: 10.1002/mds.70197.
    >> Share

  36. HEMEDA S, Elmadani M, Merzah M, Odeh A, et al
    Impact of Alcohol Intake on Parkinson's Disease Risk and Progression: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.
    Mov Disord. 2026 Jan 24. doi: 10.1002/mds.70200.
    >> Share

  37. DASH D, Bruno V, Schwingenschuh P, Lyons KE, et al
    Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
    Mov Disord. 2026 Jan 20. doi: 10.1002/mds.70184.
    >> Share

  38. OLSZEWSKA DA, Soto-Beasley AI, McCarthy A, Cerquera-Cleves C, et al
    The Assessment of RAB32 p.Ser71Arg Variant Prevalence in Parkinson's Disease Across Selected African, European, and South American Cohorts.
    Mov Disord. 2026 Jan 16. doi: 10.1002/mds.70175.
    >> Share

  39. BALACHANDAR A, Boogers A, Naghdlou S, Lozano AM, et al
    Beta-Band and Aperiodic Activity Across New and Chronic Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2026 Jan 14. doi: 10.1002/mds.70198.
    >> Share

  40. MARTINEZ-NUNEZ AE, Mills KA, Seemiller J, Morrow CB, et al
    Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment.
    Mov Disord. 2026 Jan 14. doi: 10.1002/mds.70202.
    >> Share

  41. ZHANG X, Flores-Torres MH, Christine CW, Bjornevik K, et al
    Intake of Folate, Vitamin B6, and Vitamin B12 Before and After Disease Diagnosis and the Risk of Death in Individuals with Parkinson's Disease.
    Mov Disord. 2026 Jan 12. doi: 10.1002/mds.70178.
    >> Share

  42. LIZARRAGA KJ, Wang L, McDermott MP, Lang AE, et al
    From Molecules to Populations: Is There a Role for Vitamin B6 in Parkinson's Disease?
    Mov Disord. 2026 Jan 12. doi: 10.1002/mds.70189.
    >> Share

  43. ERFMANN K, Hirschwald J, Hofacker J, Winiker K, et al
    Characteristics of Swallowing Function in People with Parkinson's Disease: A Scoping Review.
    Mov Disord. 2026 Jan 8. doi: 10.1002/mds.70164.
    >> Share

  44. LIM AW, Foo JN, Chew EG, Lim SY, et al
    Proteomic and Genetic Insights into Ancestry-Specific Associations in Parkinson's Disease.
    Mov Disord. 2026 Jan 8. doi: 10.1002/mds.70169.
    >> Share

  45. CAO LH, Wan JJ, Yan QQ, Hu Z, et al
    Re-evaluating Dystonia-Linked Gene Variants in a Large European Parkinson's Disease Cohort.
    Mov Disord. 2026 Jan 7. doi: 10.1002/mds.70173.
    >> Share

  46. BURKE R, Schoenfeld MJ, Moll CKE, Gulberti A, et al
    Modulation of Non-Rhythmic Temporal Prediction by Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) in Parkinson's Disease.
    Mov Disord. 2026 Jan 6. doi: 10.1002/mds.70165.
    >> Share

  47. WILKEN M, Granda L, Cruz I, Rossi M, et al
    The Role of Basal Ganglia Theta Oscillations in Predicting the Onset of Levodopa-Induced Dyskinesias.
    Mov Disord. 2026;41:228-233.
    >> Share

  48. DARGVAINIENE J, Helmers AK, Naumann J, Gless CA, et al
    Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound.
    Mov Disord. 2026;41:241-246.
    >> Share

  49. MIKHAEL D, Deutsch S, Mehta J, Wang S, et al
    Preoperative Functional Connectivity Predicts Antiparkinson Drug Change after Deep Brain Stimulation.
    Mov Disord. 2026;41:168-178.
    >> Share

    December 2025
  50. LIU Y, Xiao B, Huang P, Li Y, et al
    Integration of Volumetric, Iron, and Neuromelanin Magnetic Resonance Imaging Measures Effectively Differentiates Parkinson's Disease from Multiple System Atrophy.
    Mov Disord. 2025 Dec 30. doi: 10.1002/mds.70153.
    >> Share

  51. HENDERSON MJ, Chen TC, Glasstetter LM, Chen Y, et al
    The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism.
    Mov Disord. 2025 Dec 29. doi: 10.1002/mds.70168.
    >> Share

  52. GANOZA CA, Westenberger A, Paul JJ, Curado F, et al
    Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients.
    Mov Disord. 2025 Dec 24. doi: 10.1002/mds.70161.
    >> Share

  53. BEZDICEK O, Biundo R, Skorvanek M, Weintraub D, et al
    Author Response to Comment on "Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations".
    Mov Disord. 2025 Dec 16. doi: 10.1002/mds.70149.
    >> Share

  54. WOLLER JP, Gharabaghi A
    Comment on "Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations".
    Mov Disord. 2025 Dec 16. doi: 10.1002/mds.70148.
    >> Share

  55. LANG AE, Hauser RA, Kalia LV, Hersh B, et al
    LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.
    Mov Disord. 2025 Dec 12. doi: 10.1002/mds.70100.
    >> Share

  56. DORRANCE S, Patel R, Stebbins GT, Adams J, et al
    It Is Personal: What People with Parkinson's Disease Say Matters Most for Quality of Life.
    Mov Disord. 2025 Dec 12. doi: 10.1002/mds.70134.
    >> Share

  57. AL ALI J, McKay JL, Nocera JR, Isbaine F, et al
    Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease.
    Mov Disord. 2025 Dec 4. doi: 10.1002/mds.70146.
    >> Share

  58. ZHANG Q, Li Y, Mao W, Zhang H, et al
    Deep Learning to Differentiate Parkinsonian Syndromes: From Proof of Concept to Clinical Trust.
    Mov Disord. 2025 Dec 4. doi: 10.1002/mds.70139.
    >> Share

  59. ZOLFAGHARI S, Kouchache T, Delva A, Bouhadoun S, et al
    Delayed Disease Onset Report in UK Biobank: Implications for Prodromal Studies in Parkinson's Disease.
    Mov Disord. 2025 Dec 4. doi: 10.1002/mds.70147.
    >> Share

  60. PROIETTI F, Ottaviani MM, Burchi E, Vivacqua G, et al
    Vagus Nerve Stimulation in Movement Disorders, from Principles to a Systematic Review of Evidence.
    Mov Disord. 2025;40:2559-2577.
    >> Share

  61. HARING V, Selzam V, Martin-Rodriguez JF, Schwingenschuh P, et al
    Phenotypical Differentiation of Tremor Using Time Series Feature Extraction and Machine Learning.
    Mov Disord. 2025;40:2628-2640.
    >> Share

  62. CHURCHILL L, Ignatavicius A, Konuri A, Anderson J, et al
    Functional Magnetic Resonance Imaging (fMRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies.
    Mov Disord. 2025;40:2664-2677.
    >> Share

  63. WANG L, Tanglay O, Su F, Li H, et al
    Distinct AQP4 Alterations in Movement Disorders with Primary Synucleinopathy.
    Mov Disord. 2025;40:2804-2810.
    >> Share

    November 2025
  64. MARINESCU AM, Machado V, Pagano G, Muelhardt NM, et al
    Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2025 Nov 29. doi: 10.1002/mds.70103.
    >> Share

  65. JAAKKOLA E, Koponen M, Kaasinen V, Hietala J, et al
    Bipolar Disorder as a Long-Term Risk Factor for Parkinson's Disease: A Nationwide Case-Control Study.
    Mov Disord. 2025 Nov 29. doi: 10.1002/mds.70135.
    >> Share

  66. RASCOL O, Ory-Magne F, Meissner WG, Maltete D, et al
    Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).
    Mov Disord. 2025 Nov 29. doi: 10.1002/mds.70120.
    >> Share

  67. DASH D, Fabbri M, Saade J, van Munster M, et al
    Transforming Care Across Countries: Lessons from the Integrated Care Networks for Parkinson's Disease Study (iCARE-PD).
    Mov Disord. 2025 Nov 27. doi: 10.1002/mds.70110.
    >> Share

  68. ZHENG X, Cen Z, Chen X, Zhang F, et al
    A Complex FGF14 (TTC)/(TGC) Repeat Expansion in Parkinson's Disease.
    Mov Disord. 2025 Nov 24. doi: 10.1002/mds.70128.
    >> Share

  69. MARK JR, Staley HA, Titus AM, Agin-Liebes J, et al
    Parkinson's-Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa.
    Mov Disord. 2025 Nov 19. doi: 10.1002/mds.70123.
    >> Share

  70. IKEZAWA J, Yokochi F, Yamaguchi T, Abe K, et al
    Reply: "Unilateral Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Pallidothalamic Tractotomy in Parkinson's Disease: Promising Results But Uncertain Target".
    Mov Disord. 2025 Nov 18. doi: 10.1002/mds.70130.
    >> Share

  71. AUBIGNAT M
    Unilateral Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Pallidothalamic Tractotomy in Parkinson's Disease: Promising Results But Uncertain Target.
    Mov Disord. 2025 Nov 18. doi: 10.1002/mds.70131.
    >> Share

  72. PARLAR SC, Lee Y, Gan-Or Z
    GBA1 Variants with Unknown Classification Are Modest Contributors to Parkinson's Disease Susceptibility.
    Mov Disord. 2025 Nov 15. doi: 10.1002/mds.70127.
    >> Share

  73. YANG S, Zhu Y, Yu P, Huang Y, et al
    Dysfunctional Alternative Polyadenylation Modifies the Penetrance of LRRK2 Variants in Parkinson's Disease.
    Mov Disord. 2025 Nov 15. doi: 10.1002/mds.70119.
    >> Share

  74. CAMACHO M, Greenland JC, Peattie ARD, Spindler LRB, et al
    Constipation Is Linked to Neuroinflammation in Early Parkinson's Disease.
    Mov Disord. 2025 Nov 13. doi: 10.1002/mds.70102.
    >> Share

  75. PATEL B, Camacho M, Evans JR, Breen DP, et al
    The rs6971 TSPO Polymorphism Does Not Influence Disease Presentation or Progression in Parkinson's Disease rs6971 TSPO Polymorphism in PD.
    Mov Disord. 2025 Nov 3. doi: 10.1002/mds.70105.
    >> Share

  76. HIRSCHWALD J, Warnecke T
    Reply to "Comments on 'Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets'".
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70112.
    >> Share

  77. XIE T, Bloom L, McCracken E
    Comments on "Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets".
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70113.
    >> Share

  78. VIRAMETEEKUL S, Shin C, Hirczy SS, Sarva H, et al
    Assessing Digital Health Technologies for Outcome Measurement in Parkinson's Disease Drug Trials: A Systematic Review.
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70097.
    >> Share

  79. DELVA A, Zatti C, Pelletier A, Montplaisir J, et al
    Plasma Markers of Astrocytic and Axonal Integrity in Idiopathic/Isolated REM Sleep Behavior Disorder (iRBD) as Predictors of Dementia with Lewy Bodies.
    Mov Disord. 2025;40:2497-2503.
    >> Share

    October 2025
  80. RACHAO A, Silva A, Prada L, Pona-Ferreira J, et al
    Advertising to Healthcare Professionals: Insights from Parkinson's Disease in the Movement Disorders Journal.
    Mov Disord. 2025 Oct 30. doi: 10.1002/mds.70108.
    >> Share

  81. DE BIE RMA, Katzenschlager R, Bruno V, Sampaio C, et al
    Reply: "Treatment Options for Motor Fluctuations in Parkinson's Disease".
    Mov Disord. 2025 Oct 28. doi: 10.1002/mds.70109.
    >> Share

  82. HOGLINGER G, Lingor P, Hollerhage M, Trenkwalder C, et al
    Treatment Options for Motor Fluctuations in Parkinson's Disease.
    Mov Disord. 2025 Oct 28. doi: 10.1002/mds.70107.
    >> Share

  83. ALAM MS, Yu L, Stebbins GT, Mestre TA, et al
    Longitudinal Evaluation of an Abbreviated Patient-Reported Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease.
    Mov Disord. 2025 Oct 27. doi: 10.1002/mds.70096.
    >> Share

  84. HU Z, Wan JJ, Yan QQ, Fan Y, et al
    Further Investigation of Catechol-O-Methyltransferase Gene and Parkinson's Disease Susceptibility in the UK Biobank Cohort.
    Mov Disord. 2025 Oct 27. doi: 10.1002/mds.70098.
    >> Share

  85. LIN YY, Raies N, Grippe T, Gunraj CA, et al
    Transcranial Ultrasound Stimulation of Internal Globus Pallidus Region and Motor Cortex in Parkinson's Disease.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70095.
    >> Share

  86. LETA V, Zinzalias P, Batzu L, Mandal G, et al
    Effects of a Four-Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70047.
    >> Share

  87. WU Z, Zhu S, Hong R, Zhang Z, et al
    A Network Centered on the Visual-Motor Cortex Is Critically Involved in Postural Abnormality in Parkinson's Disease.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70088.
    >> Share

  88. KOCH MW, Kalia LV, Sarna J, Aquino C, et al
    Feasibility of Simon Two-Stage Futility Trials in People with Early, Symptomatically Treated Parkinson's Disease.
    Mov Disord. 2025 Oct 20. doi: 10.1002/mds.70090.
    >> Share

  89. PAPARELLA G, De Riggi M, Cannavacciuolo A, Birreci D, et al
    Analyzing the 'Bradykinesia Complex' in Parkinson's Disease.
    Mov Disord. 2025 Oct 17. doi: 10.1002/mds.70082.
    >> Share

  90. KLEINZ T, Cavallieri F, Borsche M, Toschi G, et al
    RAB32-Linked Parkinson's Disease: Deep Phenotyping, MDSGene Literature Review, and Application of SynNeurGe Criteria.
    Mov Disord. 2025 Oct 17. doi: 10.1002/mds.70037.
    >> Share

  91. LANGE LM, Fang ZH, Screven L, Tan AH, et al
    Rare but Relevant? Assessing Variants in Dystonia-Linked Genes in Parkinson's Disease.
    Mov Disord. 2025 Oct 11. doi: 10.1002/mds.70073.
    >> Share

  92. HU Z, Yan QQ, Wan JJ, Fan Y, et al
    Association of Non-Coding Repeat Expansions with Parkinson's Disease Risk: Evidence from a UK Biobank-Based Whole-Genome Sequencing Study.
    Mov Disord. 2025 Oct 11. doi: 10.1002/mds.70081.
    >> Share

  93. RICCIARDI L, Fanciulli A, Cucinotta FP, Ishihara B, et al
    Sympathetic Shift and Insular Alteration: Unravelling the Link Between Anxiety and Heart Rate Variability in Parkinson's Disease.
    Mov Disord. 2025 Oct 7. doi: 10.1002/mds.70069.
    >> Share

  94. ABDI-SARGEZEH B, Shirani S, Sharma A, Liu T, et al
    Prediction of Pathological Subthalamic Nucleus Beta Burst Occurrence in Parkinson's Disease.
    Mov Disord. 2025 Oct 3. doi: 10.1002/mds.70076.
    >> Share

  95. SADABAD FE, Volpi T, Honhar P, Tinaz S, et al
    Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual-Tracer Positron Emission Tomography Imaging Study.
    Mov Disord. 2025 Oct 3. doi: 10.1002/mds.70041.
    >> Share


  96. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S1-S60.
    >> Share


  97. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S413-S1072.
    >> Share


  98. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S229-S245.
    >> Share


  99. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S382-S412.
    >> Share


  100. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S78-S162.
    >> Share


  101. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S271-S381.
    >> Share


  102. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S163-S228.
    >> Share


  103. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S61-S77.
    >> Share


  104. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S246-S270.
    >> Share

  105. GRAYBIEL AM
    Surprises From the Basal Ganglia: Stop and Go Have New Meaning.
    Mov Disord. 2025;40:2077-2082.
    >> Share

  106. ZHANG D, Luo L, Li L, Yao J, et al
    Glymphatic Dysfunction in Non-Manifesting Carriers of LRRK2 and GBA Pathogenic Variants.
    Mov Disord. 2025;40:2189-2198.
    >> Share

    September 2025
  107. KISHORE A, Borgohain R, Puthenveedu DK, Rajan R, et al
    Reply to: "Early Indian Age at Onset of Parkinson's: A Case for a Gene-Environment Lens".
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70053.
    >> Share

  108. ONDER H, Pekgoz Z, Oztekin MF
    Early Indian Age at Onset of Parkinson's: A Case for a Gene-Environment Lens.
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70055.
    >> Share

  109. DE NEELING MGJ, Geraats S, Swinnen BEKS, Stam MJ, et al
    Temporal Dynamics of Beta Power Related to the Stun Effect in Parkinson's Disease Patients after Deep Brain Stimulation Surgery.
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70042.
    >> Share

  110. VARANDA S, Carneiro G, Pinho J
    Public Healthcare for People with Parkinson's Disease in Portugal: Rising to the Challenge.
    Mov Disord. 2025 Sep 29. doi: 10.1002/mds.70078.
    >> Share

  111. FAN Y, Hu Z, Yan QQ, Wan JJ, et al
    Reply to "Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals".
    Mov Disord. 2025 Sep 24. doi: 10.1002/mds.70060.
    >> Share

  112. MARTIN-BORNEZ M, Shar N, Nour MA, Murphy D, et al
    Does COMT Play a Role in Parkinson's Disease Susceptibility across Diverse Ancestral Populations?
    Mov Disord. 2025 Sep 23. doi: 10.1002/mds.70040.
    >> Share

  113. ZHAO Y, Pan H, Wang Y, Chen J, et al
    Expanding the Autosomal Recessive Gene Spectrum of Parkinson's Disease: A Study within the CPD10KGP.
    Mov Disord. 2025 Sep 17. doi: 10.1002/mds.70039.
    >> Share

  114. TAY YW, Ooi JCE, Lim SY, Chia YK, et al
    Very High Frequency of Early-Onset Parkinson's Disease and PRKN Mutations among Indigenous Patients in Sabah, Malaysia.
    Mov Disord. 2025 Sep 15. doi: 10.1002/mds.70015.
    >> Share

  115. VIDENOVIC A, Coffey CS, Klerman EB, Cudkowicz M, et al
    ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70009.
    >> Share

  116. ZHAO H, Hao S, Zhang P, He S, et al
    Cortical and Corticomuscular Beta-Gamma Phase-Amplitude Coupling During Different Locomotion States and the Effects of Levodopa in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70031.
    >> Share

  117. AL-AZZANI M, Weber S, Ramalingam N, Ramon M, et al
    A Novel alpha-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.
    Mov Disord. 2025 Sep 4. doi: 10.1002/mds.70030.
    >> Share

  118. DE MORAES ALVES AL, da Silva Simoes J, Trajano da Silva LR, Neto AF, et al
    Transcutaneous Spinal Magnetic Stimulation Affects Subthalamic Activity in Parkinson's Disease.
    Mov Disord. 2025 Sep 3. doi: 10.1002/mds.70035.
    >> Share

  119. SCHIESS MC, Suescun J, Martinez-Lemus JD, Green C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.70028.
    >> Share

  120. HAQ IU, Simonyan K, Napoli E, Ozelius LJ, et al
    Structural Alterations in the Gray Matter Volume in Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.30320.
    >> Share

  121. COHEN JS, Radhakrishnan H, Olm CA, Das SR, et al
    Microstructural Changes in the Tuberal Hypothalamus Correlate with Daytime Sleepiness in Lewy Body Disorders.
    Mov Disord. 2025;40:1919-1929.
    >> Share

  122. WONG JK, Horn A, Middlebrooks EH, Burns MR, et al
    A Convergent Pathway for Stimulation-Induced Dyskinesia Following Deep Brain Stimulation.
    Mov Disord. 2025;40:1901-1907.
    >> Share

    August 2025
  123. FANT A, Trova S, Monfrini E, Treves G, et al
    Compound Heterozygous Structural Variants in Cases with Unsolved PRKN-Associated Parkinson's Disease.
    Mov Disord. 2025 Aug 30. doi: 10.1002/mds.70027.
    >> Share

  124. KERSEBAUM D, Lassen J, Forstenpointner J, Sendel M, et al
    Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.
    Mov Disord. 2025 Aug 23. doi: 10.1002/mds.70004.
    >> Share

  125. ROSSI M, Farris CM, Baiardi S, Giannini G, et al
    Comparison of Two alpha-Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism.
    Mov Disord. 2025 Aug 20. doi: 10.1002/mds.70017.
    >> Share

  126. YIN KF, Gu XJ, Yu JM, Su WM, et al
    Epigenetic Mediating Mechanisms in Parkinson's Disease: The Impact of Educational Attainment on SETD1A Expression.
    Mov Disord. 2025 Aug 19. doi: 10.1002/mds.70010.
    >> Share

  127. IGNATAVICIUS A, Churchill L, Anderson J, Konuri A, et al
    Combined Dysfunction of the Amygdala and Nucleus Basalis Underlies Visual Hallucinations in Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.70011.
    >> Share

  128. FLORES-TORRES MH, Peng X, Jeanfavre S, Clish C, et al
    Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.30308.
    >> Share

  129. FIUME S, Molinari F, Vai B, Poletti S, et al
    Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in Cancer.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30321.
    >> Share

  130. FERRANTE FJ, Escobar Grisales D, Lopez MF, Lopes da Cunha P, et al
    Cognitive Phenotyping of Parkinson's Disease Patients Via Digital Analysis of Spoken Word Properties.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.70005.
    >> Share

  131. CLARKE N, Thornton P, Reader V, Lindsay N, et al
    Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30307.
    >> Share

  132. KRAUSS J, Upadhyay N, Purrer V, Borger V, et al
    Probabilistic Mapping of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy Targets in Essential Tremor and Tremor-Dominant Parkinson's Disease: Insights from a German Cohort.
    Mov Disord. 2025 Aug 8. doi: 10.1002/mds.70003.
    >> Share

  133. ZARKALI A, Thomas G, Paterson R, Hannaway N, et al
    Impaired Glymphatic Clearance, Measured Using Diffusion Tensor Image Analysis Along the Perivascular Space (DTI-ALPS), is Linked to Poor Cognitive Outcomes in Parkinson's Disease.
    Mov Disord. 2025 Aug 7. doi: 10.1002/mds.30325.
    >> Share

  134. LOO RTJ, Pavelka L, Mangone G, Khoury F, et al
    Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.
    Mov Disord. 2025;40:1604-1617.
    >> Share

  135. VARGAS GONZALEZ E, Yang Z, Dodet P, Leu-Semenescu S, et al
    Rapid Eye Movements (REMs) during Non-REM Sleep as a Marker of Alpha-Synucleinopathies.
    Mov Disord. 2025;40:1595-1603.
    >> Share

  136. BRINKERHOFF S, Nakhmani A, Varghese A, Gordon C, et al
    Paired Deep Brain Stimuli Elicit Short-Term Facilitation in Globus Pallidus Interna and Subthalamic Nucleus.
    Mov Disord. 2025;40:1636-1647.
    >> Share

    July 2025
  137. KISHORE A, Borgohain R, Puthenveedu DK, Rajan R, et al
    Demographic and Clinical Profiles of Parkinson's Disease in India: Observations from a Nation-Wide Multicenter Study.
    Mov Disord. 2025 Jul 31. doi: 10.1002/mds.30310.
    >> Share

  138. PRATUSEVICIUTE N, Lis P, Weber S, Gruchy N, et al
    Functional and Structural Characterization of LRRK2 p.V1447L in Parkinson's Disease.
    Mov Disord. 2025 Jul 30. doi: 10.1002/mds.30284.
    >> Share

  139. MATTIA GM, Chougar L, Foubert-Samier A, Meissner WG, et al
    Deep Learning to Differentiate Parkinsonian Syndromes Using Multimodal Magnetic Resonance Imaging: A Proof-of-Concept Study.
    Mov Disord. 2025 Jul 24. doi: 10.1002/mds.30300.
    >> Share

  140. ANGELINI L, van den Berg K, Dirkx M, Bologna M, et al
    Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease.
    Mov Disord. 2025 Jul 21. doi: 10.1002/mds.30299.
    >> Share

  141. VALLI A, Scheperjans F
    Subacute Painful Axonal Polyneuropathy Associated with Foslevodopa/Foscarbidopa Subcutaneous Infusion in Advanced Parkinson's Disease.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30297.
    >> Share

  142. SWINNEN BEKS, Hoy CW, Little SJ
    Towards Adaptive Deep Brain Stimulation for Non-Motor Symptoms in Parkinson's Disease?
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30212.
    >> Share

  143. BIUNDO R, Bezdicek O, Cammisuli DM, Cholerton B, et al
    Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30293.
    >> Share

  144. IKEZAWA J, Yokochi F, Yamaguchi T, Abe K, et al
    Bilateral Effects of Unilateral Pallidothalamic Tractotomy Using Focused Ultrasound in Parkinson's Disease.
    Mov Disord. 2025 Jul 17. doi: 10.1002/mds.30281.
    >> Share

  145. WEINTRAUB D, Schoen I
    The FDA Has Ended Required Blood Monitoring for Clozapine Use-Will This Impact the Management of Parkinson's Disease Psychosis?
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30295.
    >> Share

  146. CHEN PS, Liu YL, Chiang PT, Tsai HH, et al
    Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals.
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30290.
    >> Share

  147. DAI Y, Bi M, Jiao Q, Du X, et al
    Deciphering the Janus-Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis.
    Mov Disord. 2025 Jul 14. doi: 10.1002/mds.30294.
    >> Share

  148. KUNG PJ, Tsai YT, Yu RL, Lin-Wang HH, et al
    Elevated Levels of Extracellular Vesicle-Associated TAOK1 in Plasma: A Diagnostic Marker for Cognitive Decline in Parkinson's Disease Dementia and Alzheimer's Disease.
    Mov Disord. 2025 Jul 11. doi: 10.1002/mds.30287.
    >> Share

  149. MOURADIAN MM, Stoessl AJ, Lang AE
    Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.
    Mov Disord. 2025 Jul 10. doi: 10.1002/mds.30259.
    >> Share

  150. OOI JCE, Tay YW, Tan AH, Lin CH, et al
    Evaluation of a Mitochondrial Polygenic Score for Parkinson's Disease Across Ancestries.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30285.
    >> Share

  151. REIS CARNEIRO D, Morgadinho A, Araujo R
    The Emergence of a New Healthcare Paradigm for People with Parkinson's Disease in Portugal: Brief Notes on Public and Private Healthcare Systems.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30292.
    >> Share

  152. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    Unraveling the Gut-Heart Axis: Missing Links in the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30268.
    >> Share

  153. BORGHAMMER P, Van Den Berge N, Skjaerbaek C, Horsager J, et al
    Trusting Your Gut When it Comes to the Origin of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30288.
    >> Share

  154. XU X, Guo Y, Xiong Y, Min Z, et al
    Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30289.
    >> Share

  155. BOURQUE M, Morissette M, Bortolato M, Frau R, et al
    Pregnenolone Reduces L-Dopa-Induced Dyskinesias in Female Parkinsonian Monkeys.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30280.
    >> Share

  156. LI C, Ou R, Hou Y, Wei Q, et al
    Validation of Genome-Wide Association Study (GWAS)-Identified Risk Loci for Parkinson's Disease in the Chinese Population.
    Mov Disord. 2025 Jul 3. doi: 10.1002/mds.30291.
    >> Share

  157. LI C, Ou R, Hou Y, Wei Q, et al
    GBA1 Haplotypes and Age at Onset of Parkinson's Disease in the Asian Population.
    Mov Disord. 2025 Jul 2. doi: 10.1002/mds.30283.
    >> Share

  158. SIMUNI T, Gochanour C, Nair AR, Brumm MC, et al
    Neuronal alpha-Synuclein Disease Stage Progression over 5 Years.
    Mov Disord. 2025;40:1318-1330.
    >> Share

  159. GONZALEZ-ROBLES C, Athauda D, Barber TR, Barker RA, et al
    Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.
    Mov Disord. 2025;40:1307-1317.
    >> Share

  160. KAWABATA K, Krismer F, Ito M, Hara K, et al
    Trajectories of Pontine Volume in Patients with Multiple System Atrophy.
    Mov Disord. 2025;40:1369-1378.
    >> Share

  161. MIMMI S, Parrotta EI, Tolomeo AM, Maisano D, et al
    Neuronally-Derived Extracellular Vesicles Transforming Growth Factor Beta-1 Levels in Progressive Supranuclear Palsy.
    Mov Disord. 2025;40:1420-1426.
    >> Share

    June 2025
  162. ANJUM T, Raethjen J, Ding H, Koirala N, et al
    Central Pathophysiology and Brain Network Changes Related to Camptocormia in Parkinson's Disease.
    Mov Disord. 2025 Jun 29. doi: 10.1002/mds.30278.
    >> Share

  163. ESPAY AJ, Cardoso F, Frucht SJ, Imarisio A, et al
    Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS]).
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30269.
    >> Share

  164. SIMUNI T, Chahine LM, Poston KL, Kopil CM, et al
    Reply to: "Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS])".
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30272.
    >> Share

  165. HERTZ E, Rytel K, Perez G, Hao Y, et al
    Evaluation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2025 Jun 26. doi: 10.1002/mds.30273.
    >> Share

  166. HUH YE, Jang B, Jung SH, Kim D, et al
    Protective Effects of Genetic Proxies of Cognitive Reserve in Parkinson's Disease: A Longitudinal Multi-Cohort Study.
    Mov Disord. 2025 Jun 25. doi: 10.1002/mds.30276.
    >> Share

  167. PASCHEN S, Natera-Villalba E, Rodriguez-Rojas R, Del Alamo M, et al
    Lesioning the Subthalamic Nucleus Using Magnetic Resonance Imaging-Guided Focused Ultrasound in Parkinson's Disease: Subthalamotomy Effectively Describes the Procedure.
    Mov Disord. 2025 Jun 23. doi: 10.1002/mds.30271.
    >> Share

  168. ZHANG G, Guan L, Gao Y, Shi L, et al
    Sleep Stage Classification Using Subthalamic Nucleus Local Field Potentials Following Long-Term Neuromodulation in Parkinson's Disease.
    Mov Disord. 2025 Jun 12. doi: 10.1002/mds.30264.
    >> Share

  169. RICCIARDI L, Cucinotta F, Pegolo E, Abundes-Corona A, et al
    Low/High Multi-Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease.
    Mov Disord. 2025 Jun 11. doi: 10.1002/mds.30254.
    >> Share

  170. MULLER T, Kuhn W
    Is Hypomethylation of the alpha-Synuclein Gene in Parkinson's Disease Patients Related to Chronic Levodopa Intake?
    Mov Disord. 2025 Jun 9. doi: 10.1002/mds.30263.
    >> Share

  171. ERRO R, Sorrentino C, Barone P
    Plastamination: A Rising Concern for Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30253.
    >> Share

  172. LIAO Y, Wu H, Wang J, Corvol JC, et al
    Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30252.
    >> Share

  173. ANANDAPADMANABHAN R, Vishnoi A, Raman G, Thachan J, et al
    Deep Learning-Based Artificial Intelligence Algorithm to Classify Tremors from Hand-Drawn Spirals.
    Mov Disord. 2025;40:1172-1181.
    >> Share

    May 2025
  174. GROS P, Marras C, Wang X, Chiu M, et al
    Differences in Parkinson's Disease Populations: Teaching Hospitals Versus Other Settings and Implications for Clinical Trials.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30239.
    >> Share

  175. DHAWAN V, Peng S, Spetsieris PG, Eidelberg D, et al
    Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30231.
    >> Share

  176. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Reply to: "Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example".
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30247.
    >> Share

  177. GONZALEZ DA, Karstens AJ, Patel SES, Fleisher JE, et al
    The Parkinson's Disease Cognitive Composite: Lessons Forgotten from Preclinical Alzheimer's Cognitive Composites.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30246.
    >> Share

  178. FERESHTEHNEJAD SM, Moqadam R, Azizi H, Postuma RB, et al
    Distinct Longitudinal Clinical-Neuroanatomical Trajectories in Parkinson's Disease Clinical Subtypes: Insight toward Precision Medicine.
    Mov Disord. 2025 May 26. doi: 10.1002/mds.30229.
    >> Share

  179. WALSHE M, Hirschwald J, Warnecke T
    Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30241.
    >> Share

  180. VAZIRIAN F, Tian J, Cicuttini F, Jones G, et al
    Reply to: "Chronic Pain and Parkinson's Disease: Causation or Confounding?".
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30234.
    >> Share

  181. XU QH, Wang YL, Zhang BR, Tian J, et al
    Chronic Pain and Parkinson's Disease: Causation or Confounding?
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30235.
    >> Share

  182. AAMODT WW, Eickholt L, Coughlin DG, Solomon L, et al
    Sex and Racial/Ethnic Differences in End-of-Life Care Preferences in Persons with Parkinson's Disease and Related Disorders.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30240.
    >> Share

  183. VAN LAAR AD, Christine CW, Phielipp N, Larson PS, et al
    Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease.
    Mov Disord. 2025 May 20. doi: 10.1002/mds.30193.
    >> Share

  184. GAN-OR Z, Alcalay RN
    LRRK2-Associated Parkinson's Disease: Is it a Synucleinopathy After All?
    Mov Disord. 2025 May 19. doi: 10.1002/mds.30228.
    >> Share

  185. AFAAR F, Youssef P, Galper J, Chua M, et al
    Peripheral Mononuclear Cell Mitochondrial Function Associates with T-Cell Cytokines in Parkinson's Disease.
    Mov Disord. 2025 May 16. doi: 10.1002/mds.30233.
    >> Share

  186. PONS R, Pearson TS, Perez-Duenas B, Garcia-Cazorla A, et al
    Development and Preliminary Validation of a Parkinsonism-Dystonia Scale for Infants and Young Children.
    Mov Disord. 2025 May 13. doi: 10.1002/mds.30219.
    >> Share

  187. SUPPA A, Asci F, Kamble N, Chen KH, et al
    Neurophysiology of Atypical Parkinsonian Syndromes: A Study Group Position Paper.
    Mov Disord. 2025 May 12. doi: 10.1002/mds.30225.
    >> Share

  188. STRANIERO L, Rimoldi V, Cereda E, Solda G, et al
    Genetics Influences Telomere Length in Parkinson's Disease: A Study in Monozygotic Discordant Twins.
    Mov Disord. 2025 May 9. doi: 10.1002/mds.30224.
    >> Share

  189. YUCEL M, Odorfer T, Volkmann J, Zeller D, et al
    Revisiting Coactivation ("Froment's Maneuver") in Parkinson's Disease: A Physiological Approach.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30226.
    >> Share

  190. IMBALZANO G, Montanaro E, Ledda C, Donetto F, et al
    Theta-Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30218.
    >> Share

    April 2025
  191. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Are there Predictors for the Effects of Subthalamic Versus Thalamic Lesions for the Treatment of Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30216.
    >> Share

  192. AUBIGNAT M
    Does Dopamine Sensitivity Influence the Choice between Subthalamotomy and Thalamotomy for Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30215.
    >> Share

  193. DI VICO IA, Moretto M, Tamanti A, Tomelleri G, et al
    Molecular-Informed Network Analysis Unveils Fatigue-Related Functional Connectivity in Parkinson's Disease.
    Mov Disord. 2025 Apr 22. doi: 10.1002/mds.30214.
    >> Share

  194. WEINTRAUB D, Chaudhuri KR, Schrag A, Martinez-Martin P, et al
    Validation of the International Parkinson and Movement Disorder Society Non-Motor Symptoms Questionnaire (MDS-NMS-Q).
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30202.
    >> Share

  195. WIESMAN AI, Vinding MC, Tsitsi P, Svenningsson P, et al
    Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease.
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30200.
    >> Share

  196. SMITH MD, Portlock GE, Cullen A, Nodehi A, et al
    Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE).
    Mov Disord. 2025 Apr 17. doi: 10.1002/mds.30186.
    >> Share

  197. CHOU KL, Kanel P, van Emde Boas M, Roytman S, et al
    Cholinergic System Changes in Dopa-Unresponsive Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Apr 11. doi: 10.1002/mds.30196.
    >> Share

  198. LAMOS M, Bockova M, Missey F, Lubrano C, et al
    Noninvasive Temporal Interference Stimulation of the Subthalamic Nucleus in Parkinson's Disease Reduces Beta Activity.
    Mov Disord. 2025 Apr 9. doi: 10.1002/mds.30134.
    >> Share

  199. SCHOENWALD H, Bahners BH, Kannenberg S, Dembek TA, et al
    Antero-Lateral Subthalamic Nucleus Theta Stimulation Improves Verbal Fluency in Parkinson's Disease.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30185.
    >> Share

  200. CARRA RB, Garcia LAL, Menezes JR, Capato T, et al
    Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double-Blinded Evaluation.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30187.
    >> Share

  201. AMMANN C, Pagge C, Wilhelm E, Galletti C, et al
    Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease.
    Mov Disord. 2025 Apr 1. doi: 10.1002/mds.30171.
    >> Share

  202. LIU H, Zhu Q, Wang J, Qin C, et al
    Assessment of Piezo1 Expression in Urinary Exfoliated Cells as a Diagnostic Indicator for Multiple System Atrophy.
    Mov Disord. 2025;40:759-764.
    >> Share

  203. ROSSI M, Schaake S, Usnich T, Boehm J, et al
    Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.
    Mov Disord. 2025;40:605-618.
    >> Share

  204. TRUJILLO P, O'Rourke KR, Roman OC, Song AK, et al
    Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin-Sensitive Magnetic Resonance Imaging and (18)F-Fluorodopa-Positron Emission Tomography.
    Mov Disord. 2025;40:716-726.
    >> Share

    March 2025
  205. BEZDICEK O, Biundo R, Boelema S, Cammisuli DM, et al
    Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Mar 27. doi: 10.1002/mds.30166.
    >> Share

  206. GARON M, Rojo-Albuin JM, Chaudhuri KR, Rizos A, et al
    Conversion between NMSS and MDS-NMS in Parkinson's Disease.
    Mov Disord. 2025 Mar 20. doi: 10.1002/mds.30172.
    >> Share

  207. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    The Heart of the Matter: Cardiac Denervation Casts Doubt on the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30174.
    >> Share

  208. MESTRE TA, Sampaio C
    Is Parkinson Disease Better Defined Solely by Biology or as a Clinical-Biological Entity? Lessons to be Learned from Alzheimer's Disease on Biological Definition and Staging.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30173.
    >> Share

  209. YAN R, Zheng X, Yin Y, Zhang J, et al
    Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30179.
    >> Share

  210. BEHNKE JK, Peach RL, Habets JGV, Busch JL, et al
    Long-Term Stability of Spatial Distribution and Peak Dynamics of Subthalamic Beta Power in Parkinson's Disease Patients.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30169.
    >> Share

  211. SVENNINGSSON P, Odin P, Bergquist F, Wirdefeldt K, et al
    NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.
    Mov Disord. 2025 Mar 17. doi: 10.1002/mds.30175.
    >> Share

  212. WILPERT NM, Hewitt AL, Pons R, Henke MT, et al
    Patients with Allan-Herndon-Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment.
    Mov Disord. 2025 Mar 15. doi: 10.1002/mds.30152.
    >> Share

  213. COLOMBO A, Bernasconi E, Alva L, Sousa M, et al
    Finely Tuned gamma Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain-Sense Study.
    Mov Disord. 2025 Mar 13. doi: 10.1002/mds.30160.
    >> Share

  214. DE BIE RMA, Katzenschlager R, Swinnen BEKS, Peball M, et al
    Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
    Mov Disord. 2025 Mar 8. doi: 10.1002/mds.30162.
    >> Share

  215. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication-Refractory Parkinson's Disease Tremor.
    Mov Disord. 2025 Mar 3. doi: 10.1002/mds.30159.
    >> Share

    February 2025
  216. YAO P, Sharma A, Abdi-Sargezeh B, Liu T, et al
    Beta Burst Characteristics and Coupling within the Sensorimotor Cortical-Subthalamic Nucleus Circuit Dynamically Relate to Bradykinesia in Parkinson's Disease.
    Mov Disord. 2025 Feb 27. doi: 10.1002/mds.30163.
    >> Share

  217. SU D, Ji L, Cui Y, Gan L, et al
    Altered Visuomotor Network Dynamics Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Feb 25. doi: 10.1002/mds.30146.
    >> Share

  218. NI Y, Yin YN, Yu WB, Liu YQ, et al
    Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts.
    Mov Disord. 2025 Feb 19. doi: 10.1002/mds.30154.
    >> Share

  219. SONG S, Luo Z, Plassman BL, Huang X, et al
    Self-Reported Motor and Nonmotor Symptoms, Prodromal Parkinson's Disease Probability, and Incident Parkinson's Disease in US Farmers.
    Mov Disord. 2025 Feb 14. doi: 10.1002/mds.30149.
    >> Share

  220. SUN S, Madge V, Djordjevic J, Gagnon JF, et al
    Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease.
    Mov Disord. 2025 Feb 13. doi: 10.1002/mds.30148.
    >> Share

  221. WALLIN J, Forsberg A, Svenningsson P
    Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [(11)C]PBR28 PET.
    Mov Disord. 2025 Feb 6. doi: 10.1002/mds.30144.
    >> Share

  222. SANTOS-LOBATO BL
    New Insights into the Association of Pesticide Exposure and Parkinson's Disease.
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30135.
    >> Share

  223. JANSSEN DAALEN J, van der Heiden M, Meinders M, Post B, et al
    Motor Symptom Variability in Parkinson's Disease: Implications for Personalized Trial Outcomes?
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30133.
    >> Share

  224. WU Y, Xu W
    Addressing Methodological Variability and Enhancing Efficacy Assessment in Focused Ultrasound Thalamotomy for Parkinson's Tremor.
    Mov Disord. 2025 Feb 4. doi: 10.1002/mds.30136.
    >> Share

  225. LO RY
    To Trust or Not to Trust? ICD-Coded Diagnosis of Parkinson's Disease.
    Mov Disord. 2025;40:181-183.
    >> Share

  226. WIEST C, Simpson TG, Pogosyan A, Hasegawa H, et al
    Stimulation-Evoked Resonant Neural Activity in the Subthalamic Nucleus Is Modulated by Sleep.
    Mov Disord. 2025;40:351-356.
    >> Share

    January 2025
  227. GIBBON S, Breen DP, MacGillivray TJ
    Optic Disc Pallor in Parkinson's Disease: A UK Biobank Study.
    Mov Disord. 2025 Jan 30. doi: 10.1002/mds.30127.
    >> Share

  228. TOODAYAN N, Lees AJ
    Two London Memorials to "James Parkinson [1755-1824], Esq. Surgeon, Late of Hoxton-Square".
    Mov Disord. 2025 Jan 24. doi: 10.1002/mds.30115.
    >> Share

  229. FU Y, Adler GL, Youssef P, Phan K, et al
    Human Endogenous Retrovirus K in Astrocytes Is Altered in Parkinson's Disease.
    Mov Disord. 2025 Jan 22. doi: 10.1002/mds.30128.
    >> Share

  230. BRACCIA A, Golfre Andreasi N, Ghielmetti F, Aquino D, et al
    Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in a Prospective Cohort of 52 Patients with Parkinson's Disease: A Possible Critical Role of Age and Lesion Volume for Predicting Tremor Relapse.
    Mov Disord. 2025 Jan 18. doi: 10.1002/mds.30093.
    >> Share

  231. LIANG M, Chu L, Yue Z
    New Multiomic Studies Shed Light on Cellular Diversity and Neuronal Susceptibility in Parkinson's Disease.
    Mov Disord. 2025 Jan 15. doi: 10.1002/mds.30097.
    >> Share

  232. FALLETTI M, Asci F, Zampogna A, Patera M, et al
    Rigidity in Parkinson's Disease: The Objective Effect of Levodopa.
    Mov Disord. 2025 Jan 8. doi: 10.1002/mds.30114.
    >> Share

  233. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30111.
    >> Share

  234. JO S, Oh JH, Lee EJ, Choi M, et al
    Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30098.
    >> Share

  235. GUSTAVSSON EK
    Editorial on: Confirmation of RAB32 Ser71Arg involvement in Parkinson's disease.
    Mov Disord. 2025;40:5-6.
    >> Share

    December 2024
  236. TSAI SY, Tai CH, Lee YY
    Use of Transcranial Magnetic Stimulation to Probe Neuroplasticity and Predict Gait Performance After Treadmill Training in Parkinson's Disease.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30100.
    >> Share

  237. MAGISTRELLI L, Brumana M, Rimoldi V, Poggi-Longostrevi S, et al
    The RAB32 p.Ser71Arg Variant in Parkinsonisms: Insights from a Large Italian Cohort.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30103.
    >> Share

  238. RODRIGUEZ-OROZ MC, Martinez-Fernandez R, Lipsman N, Horisawa S, et al
    Bilateral Lesions in Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2024 Dec 27. doi: 10.1002/mds.30090.
    >> Share

  239. DE MENA L, Pares G, Garrido A, Pilco-Janeta DF, et al
    alpha-Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients.
    Mov Disord. 2024 Dec 23. doi: 10.1002/mds.30094.
    >> Share

  240. GUAN L, Yu H, Chen Y, Gong C, et al
    Subthalamic gamma Oscillation Underlying Rapid Eye Movement Sleep Abnormality in Parkinsonian Patients.
    Mov Disord. 2024 Dec 20. doi: 10.1002/mds.30091.
    >> Share

  241. GRILLO P, Concha-Marambio L, Pisani A, Riboldi GM, et al
    Association between the Amplification Parameters of the alpha-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Dec 18. doi: 10.1002/mds.30085.
    >> Share

  242. VAN DEN BERG KRE, Johansson ME, Dirkx MF, Bloem BR, et al
    Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates.
    Mov Disord. 2024 Dec 16. doi: 10.1002/mds.30081.
    >> Share

  243. LEE CH, Juan CH, Chen HH, Hong JP, et al
    Long-Range Temporal Correlations in Electroencephalography for Parkinson's Disease Progression.
    Mov Disord. 2024 Dec 11. doi: 10.1002/mds.30074.
    >> Share

  244. CERNERA S, Oehrn CR, Hammer LH, Shcherbakova M, et al
    Sustained Clinical Benefit of Adaptive Deep Brain Stimulation in Parkinson's Disease Using Gamma Oscillations: A Case Report.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30076.
    >> Share

  245. GOLDMAN SM, Weaver FM, Cao L, Gonzalez B, et al
    Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30075.
    >> Share

  246. WOO KA, Yoon EJ, Kim S, Kim H, et al
    Cognitive Impact of beta-Amyloid Load in the Rapid Eye Movement Sleep Behavior Disorder-Lewy Body Disease Continuum.
    Mov Disord. 2024;39:2259-2270.
    >> Share

    November 2024
  247. RABANO-SUAREZ P, Del Campo N, Benatru I, Moreau C, et al
    Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30056.
    >> Share

  248. CONTI M, D'Onofrio V, Bovenzi R, Ferrari V, et al
    Cortical Functional Connectivity Changes in the Body-First and Brain-First Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30071.
    >> Share

  249. ATTERLING BROLIN K, Schaeffer E, Kuri A, Rumrich IK, et al
    Environmental Risk Factors for Parkinson's Disease: A Critical Review and Policy Implications.
    Mov Disord. 2024 Nov 27. doi: 10.1002/mds.30067.
    >> Share

  250. HERZ DM, Blech J, Winter Y, Gonzalez-Escamilla G, et al
    Low-Frequency Deep Brain Stimulation in Non-Rapid Eye Movement Sleep Modifies Memory Retention in Parkinson's Disease.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30064.
    >> Share

  251. WANG S, Ou R, Huang J, Lin J, et al
    RAB32 Variants in a Chinese Parkinson's Disease Cohort.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30065.
    >> Share

  252. KOSZYCKI D, Taljaard M, Bradwejn J, Lee C, et al
    Interpersonal Psychotherapy for the Treatment of Depression in Parkinson's Disease: Results of a Randomized Controlled Trial.
    Mov Disord. 2024 Nov 20. doi: 10.1002/mds.30061.
    >> Share

  253. ZHAO Y, Lai Y, Darweesh SKL, Bloem BR, et al
    Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome-Wide Association Study.
    Mov Disord. 2024 Nov 12. doi: 10.1002/mds.30054.
    >> Share

  254. HWANG YS, Jo S, Lee SH, Park KW, et al
    Identification of Novel Genetic Loci Affecting Age at Onset of Parkinson's Disease: A Genome-wide Association Study.
    Mov Disord. 2024 Nov 6. doi: 10.1002/mds.30047.
    >> Share

  255. ZAGARE A, Hemedan A, Almeida C, Frangenberg D, et al
    Insulin Resistance Is a Modifying Factor for Parkinson's Disease.
    Mov Disord. 2024 Nov 5. doi: 10.1002/mds.30039.
    >> Share

  256. VAZIRIAN F, Tian J, Jane Alty, Aitken D, et al
    Chronic Musculoskeletal Pain and Risk of Incident Parkinson's Disease: A 13-Year Longitudinal Study.
    Mov Disord. 2024 Nov 2. doi: 10.1002/mds.30046.
    >> Share

  257. BALACHANDAR A, Hashim Y, Vaou O, Fasano A, et al
    Automated Sleep Detection in Movement Disorders Using Deep Brain Stimulation and Machine Learning.
    Mov Disord. 2024;39:2097-2102.
    >> Share

  258. LOPICCOLO MK, Wang Z, Eshed GM, Fierro L, et al
    Skin alpha-Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease.
    Mov Disord. 2024;39:2087-2091.
    >> Share

    October 2024
  259. CAO S, Fang X, Wang J, Sun Y, et al
    Skin Biopsy Detection of Phosphorylated alpha-Synuclein in Patients of Bullous Pemphigoid with or without Parkinson's Disease.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30045.
    >> Share

  260. STEP K, Eltaraifee E, Elsayed I, Rasaholiarison N, et al
    Advancing Parkinson's Disease Research in Africa: A Strategic Training Framework of the Global Parkinson's Genetics Program.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30051.
    >> Share

  261. RADEFELDT M, Lemke S, Chaichoompu K, Paul JJ, et al
    Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease.
    Mov Disord. 2024 Oct 26. doi: 10.1002/mds.30041.
    >> Share

  262. MAHAJAN A, Morrow CB, Seemiller J, Mills KA, et al
    The Effect of Dysautonomia on Motor, Behavioral, and Cognitive Fluctuations in Parkinson's Disease.
    Mov Disord. 2024 Oct 25. doi: 10.1002/mds.30044.
    >> Share

  263. EMMI A, Macchi V, Stocco E, Tushevski A, et al
    alpha-Synuclein Pathology in the Carotid Body: Experimental Evidence for a possible Contributor to Respiratory Impairment in Parkinson's Disease.
    Mov Disord. 2024 Oct 24. doi: 10.1002/mds.30036.
    >> Share

  264. AJALIN R, Al-Abdulrasul H, Tuisku JM, Hirvonen J, et al
    Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease.
    Mov Disord. 2024 Oct 22. doi: 10.1002/mds.30042.
    >> Share

  265. HINES K, Noecker AM, Frankemolle-Gilbert AM, Liang TW, et al
    Prospective Connectomic-Based Deep Brain Stimulation Programming for Parkinson's Disease.
    Mov Disord. 2024 Oct 21. doi: 10.1002/mds.30026.
    >> Share

  266. SLATER NM, Melzer TR, Myall DJ, Anderson TJ, et al
    Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic Resonance Imaging Evidence.
    Mov Disord. 2024 Oct 3. doi: 10.1002/mds.30023.
    >> Share

  267. CHURCHILL L, Chen YC, Lewis SJG, Matar E, et al
    Understanding REM Sleep Behavior Disorder through Functional MRI: A Systematic Review.
    Mov Disord. 2024;39:1679-1696.
    >> Share

  268. KHOSOUSI S, Sturchio A, Appleton E, Paslawski W, et al
    Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts.
    Mov Disord. 2024;39:1881-1885.
    >> Share

    September 2024
  269. COGAN G, Tesson C, Brefel-Courbon C, Lanore A, et al
    Confirmation of RAB32 Ser71Arg Involvement in Parkinson's Disease.
    Mov Disord. 2024 Sep 23. doi: 10.1002/mds.30024.
    >> Share

  270. GABBERT C, Shambetova C, Much C, Trinh J, et al
    RAB32 Variants in a German Parkinson's Disease Cohort.
    Mov Disord. 2024 Sep 19. doi: 10.1002/mds.30005.
    >> Share

  271. ARMENGOU-GARCIA L, Sanchez-Catasus CA, Aviles-Olmos I, Jimenez-Huete A, et al
    Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.30020.
    >> Share

  272. TANIGUCHI S, Kajiyama Y, Kochiyama T, Revankar G, et al
    New Insights into Freezing of Gait in Parkinson's Disease from Spectral Dynamic Causal Modeling.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.29988.
    >> Share

  273. VIEIRA SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, et al
    Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.
    Mov Disord. 2024 Sep 11. doi: 10.1002/mds.30006.
    >> Share

  274. KALIA LV, Berg D, Kordower JH, Shannon KM, et al
    Movement Disorders Society Viewpoint on Biological Frameworks of Parkinson's Disease: Current Status and Future Directions.
    Mov Disord. 2024 Sep 9. doi: 10.1002/mds.30007.
    >> Share

  275. DZIALAS V, Doering E, Eich H, Strafella AP, et al
    Houston, We Have AI Problem! Quality Issues with Neuroimaging-Based Artificial Intelligence in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Sep 5. doi: 10.1002/mds.30002.
    >> Share

  276. NIEMI KJ, Sunikka J, Soltanian-Zadeh H, Davoodi-Bojd E, et al
    Rest Tremor in Parkinson's Disease Is Associated with Ipsilateral Striatal Dopamine Transporter Binding.
    Mov Disord. 2024 Sep 3. doi: 10.1002/mds.29997.
    >> Share

  277. WIJERS A, Ravi A, Evers SMAA, Tissingh G, et al
    Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective.
    Mov Disord. 2024 Sep 2. doi: 10.1002/mds.29995.
    >> Share


  278. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S809-S858.
    >> Share


  279. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S199-S213.
    >> Share


  280. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S593-S739.
    >> Share


  281. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S290-S353.
    >> Share


  282. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S435-S592.
    >> Share


  283. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S241-S289.
    >> Share


  284. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S740-S808.
    >> Share


  285. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S214-S240.
    >> Share


  286. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S859-S896.
    >> Share


  287. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S1-S99.
    >> Share


  288. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S100-S198.
    >> Share


  289. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S354-S434.
    >> Share

    August 2024
  290. METCALFE-ROACH A, Cirstea MS, Yu AC, Ramay HR, et al
    Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2024 Aug 28. doi: 10.1002/mds.29959.
    >> Share

  291. TANG H, Lu Y, Okun MS, Donahoo WT, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
    Mov Disord. 2024 Aug 27. doi: 10.1002/mds.29992.
    >> Share

  292. GUIDA P, Martinez-Fernandez R, Manez-Miro JU, Del Alamo M, et al
    Social Cognition in Parkinson's Disease after Focused Ultrasound Subthalamotomy: A Controlled Study.
    Mov Disord. 2024 Aug 14. doi: 10.1002/mds.29945.
    >> Share

  293. LAZARO-FIGUEROA A, Hernandez-Medrano AJ, Ramirez-Pineda DB, Navarro Cadavid A, et al
    Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus?
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29719.
    >> Share

  294. YANG C, Xu Y, Feng X, Wang B, et al
    Transcranial Temporal Interference Stimulation of the Right Globus Pallidus in Parkinson's Disease.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29967.
    >> Share

  295. SOSERO YL, Bandres-Ciga S, Ferwerda B, Tocino MTP, et al
    Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29960.
    >> Share

  296. CHEYUO C, Germann J, Yamamoto K, Zibly Z, et al
    Probabilistic Refinement of Focused Ultrasound Thalamotomy Targeting for Parkinson's Disease Tremor.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29965.
    >> Share

  297. MATAR E, Tinazzi M, Edwards MJ, Bhatia KP, et al
    Functional Movement Disorder as a Prodromal Symptom of Parkinson's Disease-Clinical and Pathophysiological Insights.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29958.
    >> Share

  298. KIKUYA A, Tsukita K, Sawamura M, Yoshimura K, et al
    Distinct Clinical Implications of Patient- Versus Clinician-Rated Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2024 Aug 2. doi: 10.1002/mds.29962.
    >> Share

  299. TIAN Q, Ding J
    Advancing Parkinson's Research through Psychological Assessments of Deep Brain Stimulation Effects.
    Mov Disord. 2024;39:1429-1430.
    >> Share

  300. XIAO H, Lang L, Ye Z, Wu J, et al
    Advancing Parkinson's Research: Considerations and Future Directions.
    Mov Disord. 2024;39:1430-1431.
    >> Share

  301. SONG P, Krainc D
    Diverse Functions of Parkin in Midbrain Dopaminergic Neurons.
    Mov Disord. 2024;39:1282-1288.
    >> Share

  302. ZHENG Y, Yu Z, Cai H, Kou W, et al
    Detection of alpha-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1300-1309.
    >> Share

  303. AMRAMI A, Singh NA, Ali F, Pham NTT, et al
    Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:1402-1407.
    >> Share

    July 2024
  304. VIRAMETEEKUL S, Lees AJ, Bhidayasiri R
    Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29939.
    >> Share

  305. JUNKER J, Lange LM, Vollstedt EJ, Roopnarain K, et al
    Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29925.
    >> Share

  306. BELLINI G, Rettura F, Palermo G, Ippolito C, et al
    Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29937.
    >> Share

  307. GOEDE LL, Oxenford S, Kroneberg D, Meyer GM, et al
    Linking Invasive and Noninvasive Brain Stimulation in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29940.
    >> Share

  308. LORENZO-BETANCOR O, Mehta S, Ramchandra J, Mumuney S, et al
    Parkinson's Disease Gene Screening in Familial Cases from Central and South America.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29931.
    >> Share

  309. GIBSON LL, Weintraub D, Lemmen R, Perera G, et al
    Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jul 22. doi: 10.1002/mds.29918.
    >> Share

  310. KARIV S, Choi JW, Mirpour K, Gordon AM, et al
    Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease.
    Mov Disord. 2024 Jul 15. doi: 10.1002/mds.29928.
    >> Share

  311. ILLNER V, Novotny M, Kouba T, Tykalova T, et al
    Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Jul 12. doi: 10.1002/mds.29921.
    >> Share

  312. BERNHARDT AM, Nemati M, Boros FA, Hopfner F, et al
    alpha-Synuclein Seed Amplification Assays from Blood-Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the Evidence.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29923.
    >> Share

  313. WOOD KH, Nenert R, Miften AM, Kent GW, et al
    Diffusion Tensor Imaging-Along the Perivascular-Space Index Is Associated with Disease Progression in Parkinson's Disease.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29908.
    >> Share

  314. GOLDMAN SM, Weaver FM, Gonzalez B, Stroupe KT, et al
    Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29922.
    >> Share

  315. MUSTILE M, Kourtis D, Ladouce S, Edwards MG, et al
    Investigating the Brain Mechanisms of Externally Cued Sit-to-Stand Movement in Parkinson's Disease.
    Mov Disord. 2024 Jul 10. doi: 10.1002/mds.29889.
    >> Share

  316. DE JESUS S, Daya A, Blumberger L, Lewis MM, et al
    Prevalence of Late-Stage Parkinson's Disease in the US Healthcare System: Insights from TriNetX.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29900.
    >> Share

  317. BALTA BEYLERGIL S, Skelly P, Quagraine I, Kilbane C, et al
    Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29907.
    >> Share

  318. GUO S, Yang G
    Integrating Social Work in Late-Stage Parkinson's Care: A Multifaceted Approach.
    Mov Disord. 2024;39:1249-1250.
    >> Share

  319. KRUSE C, Dodel R, Schrag A
    Reply to Letter to the Editor-MDS-23-0498.R2/MDS-24-0318.R1.
    Mov Disord. 2024;39:1251-1252.
    >> Share

  320. ADLER CH, Halverson M, Zhang N, Shill HA, et al
    Conjugal Synucleinopathies: A Clinicopathologic Study.
    Mov Disord. 2024;39:1212-1217.
    >> Share

  321. ZHENG Y, Li Y, Cai H, Kou W, et al
    Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024;39:1179-1189.
    >> Share

    June 2024
  322. BURRE J, Edwards RH, Halliday G, Lang AE, et al
    Research Priorities on the Role of alpha-Synuclein in Parkinson's Disease Pathogenesis.
    Mov Disord. 2024 Jun 30. doi: 10.1002/mds.29897.
    >> Share

  323. AKCIMEN F, van Midden V, Akerman SC, Makarious MB, et al
    Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29892.
    >> Share

  324. COGAN G, Daida K, Billingsley KJ, Tesson C, et al
    Long-Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early-Onset Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29914.
    >> Share

  325. FABBRI M, Rascol O, Foltynie T, Carroll C, et al
    Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease.
    Mov Disord. 2024 Jun 26. doi: 10.1002/mds.29899.
    >> Share

  326. LEODORI G, De Bartolo MI, Piervincenzi C, Mancuso M, et al
    Mapping Motor Cortical Network Excitability and Connectivity Changes in De Novo Parkinson's Disease.
    Mov Disord. 2024 Jun 24. doi: 10.1002/mds.29901.
    >> Share

  327. WANG X, Fu S, Yoo K, Wang X, et al
    Individualized Structural Perturbations on Normative Brain Connectome Restrict Deep Brain Stimulation Outcomes in Parkinson's Disease.
    Mov Disord. 2024 Jun 18. doi: 10.1002/mds.29874.
    >> Share

  328. KIMURA Y, Mochizuki H
    Targeting Glucagon-Like Peptide 1 Signaling: A Potential Disease Modifying Therapy for Parkinson's Disease.
    Mov Disord. 2024 Jun 14. doi: 10.1002/mds.29884.
    >> Share

  329. BREFEL-COURBON C, Harroch E, Marques A, Devos D, et al
    Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
    Mov Disord. 2024 Jun 8. doi: 10.1002/mds.29878.
    >> Share

  330. JENSEN I, Heine J, Ruf VC, Compta Y, et al
    Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.
    Mov Disord. 2024 Jun 7. doi: 10.1002/mds.29879.
    >> Share

  331. KORCZYN AD
    Rethinking Parkinson's Disease: A Syndromic Perspective.
    Mov Disord. 2024;39:1079-1080.
    >> Share

  332. LEODORI G, Mancuso M, Marchet F, Belvisi D, et al
    The Role of the Motor Cortex in the Parkinsonian Tremor Network: Is it Time for an Upgrade?
    Mov Disord. 2024;39:1084.
    >> Share

  333. OUTEIRO TF, Antonini A, Ferreira JJ
    Reply to: "Rethinking Parkinson's Disease: A Syndromic Perspective".
    Mov Disord. 2024;39:1080-1081.
    >> Share

  334. SCHNEIDER RB, Mills KA, Nirenberg MJ, Dobkin RD, et al
    Defining the Importance of Minor Hallucinations in Parkinson's Disease.
    Mov Disord. 2024;39:1083.
    >> Share

  335. OLANOW CW, McIntyre D, Matarazzo M, Leinonen M, et al
    Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
    Mov Disord. 2024;39:945-954.
    >> Share

  336. BUUR L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, et al
    Randomized Phase I Trial of the alpha-Synuclein Antibody Lu AF82422.
    Mov Disord. 2024;39:936-944.
    >> Share

  337. SIMONET C, Perez-Carbonell L, Galmes-Ordinas MA, Huxford BFR, et al
    The Motor Dysfunction Seen in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1054-1059.
    >> Share

  338. AVENALI M, Cerri S, Palmieri I, Ongari G, et al
    Functional Study of SNCA p.V15A Variant: Further Linking alpha-Synuclein and Glucocerebrosidase.
    Mov Disord. 2024;39:1060-1065.
    >> Share

    May 2024
  339. GRIPPE T, Shamli-Oghli Y, Darmani G, Nankoo JF, et al
    Plasticity-Induced Effects of Theta Burst Transcranial Ultrasound Stimulation in Parkinson's Disease.
    Mov Disord. 2024 May 24. doi: 10.1002/mds.29836.
    >> Share

  340. VAN MIDDEN V, Simoncic U, Pirtosek Z, Kojovic M, et al
    The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait-A Randomized Motion Sensor Study.
    Mov Disord. 2024 May 17. doi: 10.1002/mds.29826.
    >> Share

  341. ZHANG J, Liu Y, Zhao C
    SNCA-Related Parkinson's Disease Caused by Complete Chromosome 4 Paternal Uniparental Disomy.
    Mov Disord. 2024 May 13. doi: 10.1002/mds.29823.
    >> Share

  342. HEISS JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, et al
    Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
    Mov Disord. 2024 May 8. doi: 10.1002/mds.29820.
    >> Share

  343. XIAO H, Lang L, Ye Z, Wu J, et al
    Subthalamic Nucleus Stimulation Modulates Cognitive Theory of Mind in Parkinson's Disease.
    Mov Disord. 2024 May 2. doi: 10.1002/mds.29830.
    >> Share

  344. MA JH, Dong C, Qiao HW, Barret O, et al
    Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:847-854.
    >> Share

    April 2024
  345. DODET P, Houot M, Leu-Semenescu S, Gaurav R, et al
    Isolated REM Sleep without Atonia Is Not Equivalent to REM Sleep Behavior Disorder in Early-Stage Parkinson's Disease.
    Mov Disord. 2024 Apr 26. doi: 10.1002/mds.29813.
    >> Share

  346. MONCHI O, Pinilla-Monsalve GD, Almgren H, Ghahremani M, et al
    White Matter Microstructural Underpinnings of Mild Behavioral Impairment in Parkinson's Disease.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29804.
    >> Share

  347. SENKEVICH K, Miliukhina I, Zhuravlev A, Shumilova M, et al
    Autosomal Dominant Parkinson's Disease Caused by SNCA p.E46K Mutation in a Family with Russian Ancestry.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29821.
    >> Share

  348. KLUGE A, Schaeffer E, Bunk J, Sommerauer M, et al
    Detecting Misfolded alpha-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease.
    Mov Disord. 2024 Apr 23. doi: 10.1002/mds.29766.
    >> Share

  349. FREQUIN HL, Verschuur CVM, Suwijn SR, Boel JA, et al
    Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease.
    Mov Disord. 2024 Apr 21. doi: 10.1002/mds.29796.
    >> Share

  350. WANG Y, Li H, Song N, Xie J, et al
    Yeast Prion Protein Sup35 Initiates alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2024 Apr 16. doi: 10.1002/mds.29810.
    >> Share

  351. LASS J, Luth T, Schluter K, Schaake S, et al
    Stability of Mosaic Divergent Repeat Interruptions in X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2024 Apr 14. doi: 10.1002/mds.29809.
    >> Share

  352. SHARMA K, Kishore A, Lechado-Terradas A, Passannanti R, et al
    A Novel PINK1 p.F385S Loss-of-Function Mutation in an Indian Family with Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29792.
    >> Share

  353. NIEMI KJ, Huovinen A, Jaakkola E, Glerean E, et al
    Bodily Maps of Symptoms and Emotions in Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29785.
    >> Share

  354. DU J, Zhang P, Tan Y, Gao C, et al
    Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short-Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease (PD).
    Mov Disord. 2024 Apr 1. doi: 10.1002/mds.29803.
    >> Share

  355. ONDER H
    Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:758-759.
    >> Share

  356. PETERS J, Maamary J, Kyle K, Olsen N, et al
    Reply to: Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:759-760.
    >> Share

  357. BOOGERS A, Fasano A
    Reply to: Comment on: A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2024;39:761.
    >> Share

  358. XIE T, Warnke PC
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:760-761.
    >> Share

  359. PATEL J, Dawson VL, Dawson TM
    Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition.
    Mov Disord. 2024;39:644-650.
    >> Share

  360. KORNILOV E, Baker Erdman H, Kahana E, Fireman S, et al
    Interleaved Propofol-Ketamine Maintains DBS Physiology and Hemodynamic Stability: A Double-Blind Randomized Controlled Trial.
    Mov Disord. 2024;39:694-705.
    >> Share

  361. STEINA A, Sure S, Butz M, Vesper J, et al
    Mapping Subcortico-Cortical Coupling-A Comparison of Thalamic and Subthalamic Oscillations.
    Mov Disord. 2024;39:684-693.
    >> Share

    March 2024

  362. Correction to "Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus".
    Mov Disord. 2024 Mar 29. doi: 10.1002/mds.29805.
    >> Share

  363. VERONESE N, Nova A, Fazia T, Riggi E, et al
    Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson's Disease.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29778.
    >> Share

  364. DING H, Nasseroleslami B, Mirzac D, Isaias IU, et al
    Re-emergent Tremor in Parkinson's Disease: Evidence of Pathologic beta and Prokinetic gamma Activity.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29771.
    >> Share

  365. LIU Y, Bainbridge J, Sillau S, Rajkovic S, et al
    Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Mar 15. doi: 10.1002/mds.29768.
    >> Share

  366. FRIEDMAN JH
    A New Definition of Psychosis Is Needed in Parkinson's Disease.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29786.
    >> Share

  367. ZOETEWEI D, Herman T, Ginis P, Palmerini L, et al
    On-Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29762.
    >> Share

  368. CHOUGAR L, Faucher A, Faouzi J, Lejeune FX, et al
    Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29760.
    >> Share

  369. MENEZES JR, Nunes GA, Carra RB, da Silva Simoes J, et al
    Trans-Spinal Theta Burst Magnetic Stimulation in Parkinson's Disease and Gait Disorders.
    Mov Disord. 2024 Mar 13. doi: 10.1002/mds.29776.
    >> Share

  370. PARDO J, Montal V, Campabadal A, Oltra J, et al
    Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Mar 8. doi: 10.1002/mds.29761.
    >> Share

  371. SISODIA V, Malekzadeh A, Verwijk E, Schuurman PR, et al
    Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Mar 1. doi: 10.1002/mds.29772.
    >> Share

  372. BINGHAM CS, McIntyre CC
    Coupled Activation of the Hyperdirect and Cerebellothalamic Pathways with Zona Incerta Deep Brain Stimulation.
    Mov Disord. 2024;39:539-545.
    >> Share

  373. LEWITT PA, Stebbins GT, Christensen KV, Tan R, et al
    Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
    Mov Disord. 2024;39:613-618.
    >> Share

  374. THOMSEN M, Marth K, Loens S, Everding J, et al
    Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes.
    Mov Disord. 2024;39:526-538.
    >> Share

  375. MUNCHAU A, Klein C, Beste C
    Rethinking Movement Disorders.
    Mov Disord. 2024;39:472-484.
    >> Share

  376. KAMATH SD, Holla VV, Phulpagar P, Kamble N, et al
    Clinicogenetic Characterization of Patients with PD and Heterozygous GBA1 Variants in an Indian Cohort.
    Mov Disord. 2024;39:628-630.
    >> Share

    February 2024
  377. KRUSE C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, et al
    Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
    Mov Disord. 2024 Feb 29. doi: 10.1002/mds.29718.
    >> Share

  378. WILKEN M, Andres DS, Bianchi G, Hallett M, et al
    Persistence of Basal Ganglia Oscillatory Activity During Tremor Attenuation by Movement in Parkinson's Disease Patients.
    Mov Disord. 2024 Feb 28. doi: 10.1002/mds.29679.
    >> Share

  379. OJO OO, Bandres-Ciga S, Makarious MB, Crea PW, et al
    GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29753.
    >> Share

  380. DORSEY ER, Kinel D, Pawlik ME, Zafar M, et al
    Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29723.
    >> Share

  381. AMBROSINI E, Cancilla R, Paul JJ, Bauer P, et al
    Pure Parkinsonism as Possible Phenotype Expansion of THAP1-Related Disorders.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29745.
    >> Share

  382. SOLIS GP, Larasati YA, Thiel M, Koval A, et al
    GNAO1 Mutations Affecting the N-Terminal alpha-Helix of Galphao Lead to Parkinsonism.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29720.
    >> Share

  383. PAPAGIANNAKIS N, Liu H, Koros C, Simitsi AM, et al
    Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29739.
    >> Share

  384. WEINTRAUB D, Marras C, Amara A, Anderson KE, et al
    Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease.
    Mov Disord. 2024 Feb 6. doi: 10.1002/mds.29725.
    >> Share

  385. KULCSAROVA K, Skorvanek M
    Challenges and Future of the International Parkinson and Movement Disorder Society Prodromal Parkinson's Disease Criteria: Are We On the Right Track?
    Mov Disord. 2024 Feb 4. doi: 10.1002/mds.29724.
    >> Share

  386. YUAN X, Wan L, Chen Z, Long Z, et al
    Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study.
    Mov Disord. 2024;39:391-399.
    >> Share

    January 2024
  387. FOLLETT J, Guenther D, Xoi L, Amouri R, et al
    Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab-Berbers.
    Mov Disord. 2024 Jan 31. doi: 10.1002/mds.29735.
    >> Share

  388. MANGONE G, Tosin MHS, Goetz CG, Stebbins GT, et al
    Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29710.
    >> Share

  389. DAMIER P, Degos B, Castelonovo G, Anheim M, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29726.
    >> Share

  390. MARRAS C, Fereshtehnejad SM, Berg D, Bohnen NI, et al
    Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29708.
    >> Share

  391. EIDEM LE, Birkeland E, Austdal M, Bardsen K, et al
    Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29715.
    >> Share

  392. DEBOVE I, Paschen S, Amstutz D, Cardoso F, et al
    Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
    Mov Disord. 2024 Jan 17. doi: 10.1002/mds.29700.
    >> Share

  393. ROSE KN, Schwarzschild MA, Gomperts SN
    Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29707.
    >> Share

  394. MULLER S, Kassubek J, Hold ST, Kasper DC, et al
    Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29686.
    >> Share

  395. TUNNICLIFFE L, Weil RS, Breuer J, Rodriguez-Barradas MC, et al
    Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29701.
    >> Share

  396. AMMANN C, Oliviero A, Obeso JA, Foffani G, et al
    Motor Cortex Disinhibition Is Not Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2024 Jan 5. doi: 10.1002/mds.29709.
    >> Share

  397. THOMAS GEC, Hannaway N, Zarkali A, Shmueli K, et al
    Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29702.
    >> Share

  398. SICILIANO M, Tessitore A, Morgante F, Goldman JG, et al
    Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29649.
    >> Share

  399. DOMEN CH, Sillau S, Liu Y, Leehey MA, et al
    Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2024;39:222-223.
    >> Share

  400. GAN-OR Z, Alcalay RN
    Genetics of Parkinson's Disease in Underrepresented Populations: New Studies Pave the Way.
    Mov Disord. 2024;39:1-2.
    >> Share

  401. BEUDEL M
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:223-224.
    >> Share

  402. SAMPSON TR
    Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut.
    Mov Disord. 2024;39:3-5.
    >> Share

  403. RAU A, Hosp JA, Rijntjes M, Weiller C, et al
    Cerebellar, Not Nigrostriatal Degeneration Impairs Dexterity in Multiple System Atrophy.
    Mov Disord. 2024;39:130-140.
    >> Share

  404. KRISMER F, Peran P, Beliveau V, Seppi K, et al
    Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
    Mov Disord. 2024;39:119-129.
    >> Share

  405. HILL ME, Johnson LA, Wang J, Escobar Sanabria D, et al
    Paradoxical Modulation of STN beta-Band Activity with Medication Compared to Deep Brain Stimulation.
    Mov Disord. 2024;39:192-197.
    >> Share

    December 2023
  406. MIRELMAN A, Volkov J, Salomon A, Gazit E, et al
    Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
    Mov Disord. 2023 Dec 27. doi: 10.1002/mds.29689.
    >> Share

  407. ONG S, Funayama M, Mangyoku Y, Kawai H, et al
    Investigation of 22q11.2 Deletion in Japanese Early-Onset Parkinsonism.
    Mov Disord. 2023 Dec 25. doi: 10.1002/mds.29692.
    >> Share

  408. JANSSEN DAALEN JM, Koopman WJH, Saris CGJ, Meinders MJ, et al
    The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Mov Disord. 2023 Dec 23. doi: 10.1002/mds.29688.
    >> Share

  409. BAIK K, Kim YJ, Park M, Chung SJ, et al
    Functional Brain Networks of Minor and Well-Structured Major Hallucinations in Parkinson's Disease.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29681.
    >> Share

  410. GONZALEZ-ROBLES C, Bartlett M, Burnell M, Clarke CS, et al
    Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
    >> Share

  411. TUNOLD JA, Tan MMX, Toft M, Ross O, et al
    Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk.
    Mov Disord. 2023 Dec 20. doi: 10.1002/mds.29698.
    >> Share

  412. ESPAY AJ, Hauser RA, Dhall R, Thakkar S, et al
    Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29685.
    >> Share

  413. MARANO M, Anzini G, Saltarocchi L, Ricciuti R, et al
    Left Vagus Stimulation Modulates Contralateral Subthalamic beta Power Improving the Gait in Parkinson's Disease.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29690.
    >> Share

  414. CARDOSO F, Goetz CG, Mestre TA, Sampaio C, et al
    A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
    Mov Disord. 2023 Dec 13. doi: 10.1002/mds.29683.
    >> Share

  415. MYLIUS V, Baars JH, Witt K, Benninger D, et al
    Deep Brain Stimulation Improves Parkinson's Disease-Associated Pain by Decreasing Spinal Nociception.
    Mov Disord. 2023 Dec 9. doi: 10.1002/mds.29666.
    >> Share

  416. KIM DJ, Isidro-Perez AL, Doering M, Llibre-Rodriguez JJ, et al
    Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
    Mov Disord. 2023 Dec 8. doi: 10.1002/mds.29682.
    >> Share

  417. BRISSENDEN JA, Scerbak T, Albin RL, Lee TG, et al
    Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Mov Disord. 2023 Dec 7. doi: 10.1002/mds.29659.
    >> Share

  418. FIORENZATO E, Moaveninejad S, Weis L, Biundo R, et al
    Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2023 Dec 6. doi: 10.1002/mds.29678.
    >> Share

  419. MULLER T, Kuhn W
    An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease.
    Mov Disord. 2023;38:2319-2320.
    >> Share

  420. NAMBU A, Chiken S, Sano H, Hatanaka N, et al
    Dynamic Activity Model of Movement Disorders: The Fundamental Role of the Hyperdirect Pathway.
    Mov Disord. 2023;38:2145-2150.
    >> Share

  421. ZHENG Y, Cai H, Wang X, Zhang N, et al
    Erythrocytic alpha-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:2315-2317.
    >> Share

    November 2023
  422. ANDREWS SV, Kukkle PL, Menon R, Geetha TS, et al
    The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in India.
    Mov Disord. 2023 Nov 28. doi: 10.1002/mds.29676.
    >> Share

  423. WANG J, Li H, Jia J, Shao X, et al
    Progressive Cerebrovascular Reactivity Reduction Occurs in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2023 Nov 27. doi: 10.1002/mds.29671.
    >> Share

  424. ONGARI G, Ghezzi C, Di Martino D, Pisani A, et al
    Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease?
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29643.
    >> Share

  425. DI FOLCO C, Couronne R, Arnulf I, Mangone G, et al
    Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease.
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29662.
    >> Share


  426. Correction to Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Nov 22. doi: 10.1002/mds.29660.
    >> Share

  427. MA DR, Li SJ, Shi JJ, Liang YY, et al
    Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes.
    Mov Disord. 2023 Nov 21. doi: 10.1002/mds.29598.
    >> Share

  428. KIM A, Martinez-Valbuena I, Keith JL, Kovacs GG, et al
    Misfolded alpha-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable alpha-Synuclein Pathology.
    Mov Disord. 2023 Nov 20. doi: 10.1002/mds.29665.
    >> Share

  429. BOOGERS A, Fasano A
    A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Nov 15. doi: 10.1002/mds.29656.
    >> Share

  430. KERESTES R, Laansma MA, Owens-Walton C, Perry A, et al
    Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
    Mov Disord. 2023 Nov 14. doi: 10.1002/mds.29611.
    >> Share

  431. OERTEL WH, Paule E, Hasemann T, Sittig E, et al
    Reduced Gastric Contraction in Rapid-Eye-Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
    Mov Disord. 2023 Nov 13. doi: 10.1002/mds.29652.
    >> Share

  432. KONERU V, Espay AJ, Cole AJ, Weintraub D, et al
    The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
    Mov Disord. 2023 Nov 8. doi: 10.1002/mds.29627.
    >> Share

  433. DAIDA K, Funayama M, Billingsley KJ, Malik L, et al
    Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Mov Disord. 2023 Nov 5. doi: 10.1002/mds.29610.
    >> Share

  434. SAFFIE AWAD P, Teixeira-Dos-Santos D, Santos-Lobato BL, Camargos S, et al
    Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Nov 3. doi: 10.1002/mds.29614.
    >> Share

  435. PAL GD, Corcos DM, Metman LV, Israel Z, et al
    Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
    Mov Disord. 2023 Nov 2. doi: 10.1002/mds.29647.
    >> Share


  436. The Future of Parkinson's Disease: Improving Care & Driving Research.
    Mov Disord. 2023;38 Suppl 2:S1-S21.
    >> Share

  437. BERGER SL, Seemiller J, Rosenthal LS
    Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications.
    Mov Disord. 2023;38:1990-1991.
    >> Share

  438. VASILEVSKAYA A, Martinez-Valbuena I, Anastassiadis C, Taghdiri F, et al
    Misfolded alpha-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
    Mov Disord. 2023;38:2125-2131.
    >> Share

  439. DI LUCA DG, Ramirez-Gomez C, Germann J, Santyr B, et al
    Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy.
    Mov Disord. 2023;38:2121-2125.
    >> Share

    October 2023
  440. OLANOW CW, Hauser RA, Burdick DJ, Dhall R, et al
    A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
    Mov Disord. 2023 Oct 27. doi: 10.1002/mds.29642.
    >> Share

  441. PAHWA R, Merola A, Soileau M, Alobaidi A, et al
    Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
    Mov Disord. 2023 Oct 25. doi: 10.1002/mds.29624.
    >> Share

  442. BOUGOU V, Vanhoyland M, Decramer T, Van Hoylandt A, et al
    Active and Passive Cycling Decrease Subthalamic beta Oscillations in Parkinson's Disease.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29632.
    >> Share

  443. CONTI M, Guerra A, Pierantozzi M, Bovenzi R, et al
    Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29615.
    >> Share

  444. ALBIN R, Grotewold N
    What is the Parkinson Pandemic?
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29637.
    >> Share

  445. WOO KA, Joun JH, Yoon EJ, Lee CY, et al
    Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease.
    Mov Disord. 2023 Oct 17. doi: 10.1002/mds.29623.
    >> Share

  446. BUSCH JL, Kaplan J, Bahners BH, Roediger J, et al
    Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Oct 12. doi: 10.1002/mds.29626.
    >> Share

  447. SAMUEL N, Ding MYR, Sarica C, Darmani G, et al
    Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study.
    Mov Disord. 2023 Oct 9. doi: 10.1002/mds.29622.
    >> Share

  448. YANG Y, Stewart T, Zhang C, Wang P, et al
    Erythrocytic alpha-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
    Mov Disord. 2023 Oct 5. doi: 10.1002/mds.29620.
    >> Share

  449. WAN L, Fu Y, Chen Z, Long Z, et al
    No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts.
    Mov Disord. 2023;38:1956-1961.
    >> Share

  450. HU Y, Ma TC, Alberico SL, Ding Y, et al
    Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
    Mov Disord. 2023;38:1850-1860.
    >> Share

  451. GROSSMANN D, Malburg N, Glass H, Weeren V, et al
    Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
    Mov Disord. 2023;38:1822-1836.
    >> Share

    September 2023
  452. JANSSEN DAALEN JM, Oosterhof TH, Bloem BR, Darweesh SKL, et al
    Wearables for Parkinson's: Fast-Paced toward Novel Outcome Measures.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29608.
    >> Share

  453. SATOH R, Weigand SD, Pham NTT, Ali F, et al
    Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29613.
    >> Share

  454. DI FONZO A, Percetti M, Monfrini E, Palmieri I, et al
    Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.
    Mov Disord. 2023 Sep 26. doi: 10.1002/mds.29617.
    >> Share

  455. TOFFOLI M, Schapira AHV, Proukakis C
    Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease.
    Mov Disord. 2023 Sep 22. doi: 10.1002/mds.29609.
    >> Share

  456. NATALE G, Colella M, De Carluccio M, Lelli D, et al
    Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
    Mov Disord. 2023 Sep 12. doi: 10.1002/mds.29599.
    >> Share

  457. ZHAO Y, Ray A, Broberg K, Kippler M, et al
    Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
    Mov Disord. 2023 Sep 7. doi: 10.1002/mds.29602.
    >> Share

  458. BOOIJ J, Tellier SP, Seibyl J, Vriend C, et al
    Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29597.
    >> Share

  459. MARKAKI I, Paslawski W, Ntetsika T, Engesvik L, et al
    Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29601.
    >> Share


  460. Correction to "Olfactory Neuron Substance P Is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction".
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29600.
    >> Share

  461. FINK A, Dodel R, Georges D, Doblhammer G, et al
    The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
    Mov Disord. 2023 Sep 1. doi: 10.1002/mds.29596.
    >> Share

  462. BOON LI, Buijink AWG
    Parkinsonian Tremor: Shaking in Synchrony.
    Mov Disord. 2023;38:1582-1584.
    >> Share

  463. GONZALEZ-LATAPI P, Lo RY
    Bone First or Brain First: "Picking at the Bones" of Parkinson's Disease.
    Mov Disord. 2023;38:1579-1581.
    >> Share

  464. ZHANG D, Zhou L, Yao J, Shi Y, et al
    Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder.
    Mov Disord. 2023;38:1645-1654.
    >> Share

    August 2023
  465. SUN H, Gan C, Wang L, Ji M, et al
    Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
    Mov Disord. 2023 Aug 30. doi: 10.1002/mds.29595.
    >> Share

  466. TOTSUNE T, Baba T, Sugimura Y, Oizumi H, et al
    Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
    Mov Disord. 2023 Aug 28. doi: 10.1002/mds.29582.
    >> Share

  467. WEINTRAUB D
    What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2023 Aug 23. doi: 10.1002/mds.29590.
    >> Share

  468. ANDICA C, Kamagata K, Uchida W, Saito Y, et al
    Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
    Mov Disord. 2023 Aug 22. doi: 10.1002/mds.29578.
    >> Share

  469. PARK KY, Jung JH, Hwang HS, Park HK, et al
    Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29579.
    >> Share

  470. TRESSERRA-RIMBAU A, Thompson AS, Bondonno N, Jennings A, et al
    Plant-Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29580.
    >> Share

  471. DAI L, Wang J, Zhang X, Yan M, et al
    27-Hydroxycholesterol Drives the Spread of alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2023 Aug 18. doi: 10.1002/mds.29577.
    >> Share

  472. BAR-ON M, Baharav S, Katzir Z, Mirelman A, et al
    Task-Related Reorganization of Cognitive Network in Parkinson's Disease Using Electrophysiology.
    Mov Disord. 2023 Aug 8. doi: 10.1002/mds.29571.
    >> Share

  473. GAARE JJ, Brugger K, Nido GS, Tzoulis C, et al
    DNA Methylation Age Acceleration Is Not Associated with Age of Onset in Parkinson's Disease.
    Mov Disord. 2023 Aug 7. doi: 10.1002/mds.29574.
    >> Share

  474. CHU Y, Kordower JH
    Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Mov Disord. 2023 Aug 6. doi: 10.1002/mds.29518.
    >> Share

  475. TA M, Blauwendraat C, Antar T, Leonard HL, et al
    Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29511.
    >> Share

  476. CHUA MMJ, Blitz SE, Ng PR, Segar DJ, et al
    Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29569.
    >> Share

  477. TIAN Y, Ma G, Li H, Zeng Y, et al
    Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease.
    Mov Disord. 2023 Aug 3. doi: 10.1002/mds.29572.
    >> Share

  478. AQUINO C, Luo L, Agarwal P, Garg K, et al
    Deep Brain Stimulation as an Exclusion Criteria in Parkinson's Disease Studies: Time to Rethink?
    Mov Disord. 2023 Aug 2. doi: 10.1002/mds.29554.
    >> Share

  479. VIRAMETEEKUL S, de Pablo-Fernandez E
    Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
    Mov Disord. 2023;38:1574-1575.
    >> Share

  480. GOETZ CG, Zou H, Stebbins GT, Schrag A, et al
    Reply to: Comment on "Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1564.
    >> Share

  481. KOVACS N, Aschermann Z, Harmat M, Rohonczi M, et al
    Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1563-1564.
    >> Share

  482. BEACH TG, Adler CH, Shill HA, Zhang N, et al
    Accuracy of the Early Diagnosis of Parkinson's Disease.
    Mov Disord. 2023;38:1573-1574.
    >> Share

  483. KLIETZ M, Mahmoudi N, Maudsley AA, Sheriff S, et al
    Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:1503-1514.
    >> Share

  484. AGIN-LIEBES J, Hickman RA, Vonsattel JP, Faust PL, et al
    Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
    Mov Disord. 2023;38:1541-1545.
    >> Share


  485. Abstracts of the 2023 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2023;38 Suppl 1:S1-S871.
    >> Share

  486. ALBANESE A, Bhatia KP, Cardoso F, Comella C, et al
    Isolated Cervical Dystonia: Diagnosis and Classification.
    Mov Disord. 2023;38:1367-1378.
    >> Share

    July 2023
  487. LABRADOR-ESPINOSA MA, Silva-Rodriguez J, Reina-Castillo MI, Mir P, et al
    Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-beta Status in Parkinson's disease-Related Cognitive Decline.
    Mov Disord. 2023 Jul 26. doi: 10.1002/mds.29564.
    >> Share

  488. BORSCHE M, Berg D
    Blood-Based alpha-Synuclein Seeding-A New Era for Identifying Parkinsonian Syndromes.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29555.
    >> Share

  489. JEONG SH, Kim SH, Park CW, Lee HS, et al
    Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29565.
    >> Share

  490. LUTH T, Gabbert C, Koch S, Konig IR, et al
    Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Mov Disord. 2023 Jul 21. doi: 10.1002/mds.29563.
    >> Share

  491. LEAL TP, Rao SC, French-Kwawu JN, Gouveia MH, et al
    X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.
    Mov Disord. 2023 Jul 20. doi: 10.1002/mds.29508.
    >> Share

  492. XYLAKI M, Chopra A, Weber S, Bartl M, et al
    Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Jul 14. doi: 10.1002/mds.29497.
    >> Share

  493. TESSON C, Bouchetara MS, Ferrien M, Lesage S, et al
    Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease.
    Mov Disord. 2023 Jul 11. doi: 10.1002/mds.29533.
    >> Share

  494. ZHUPARRIS A, Thijssen E, Elzinga WO, Makai-Boloni S, et al
    Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
    Mov Disord. 2023 Jul 4. doi: 10.1002/mds.29520.
    >> Share

  495. ARSHAD U, Rahman F, Hanan N, Chen C, et al
    Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design.
    Mov Disord. 2023 Jul 3. doi: 10.1002/mds.29514.
    >> Share

  496. TURNER TH, Hinson VK
    Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2023;38:1125-1126.
    >> Share

  497. PU J, Lin L, Jiang H, Hu Z, et al
    Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
    Mov Disord. 2023;38:1273-1281.
    >> Share

  498. ZOU H, Goetz CG, Stebbins GT, Schrag A, et al
    Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
    Mov Disord. 2023;38:1363-1364.
    >> Share

    June 2023
  499. SCHLIESSER P, Struebing FL, Northoff BH, Kurz A, et al
    Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29515.
    >> Share

  500. VON BELOW D, Wallerstedt SM, Bergquist F
    Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29517.
    >> Share

  501. SENKEVICH K, Beletskaia M, Dworkind A, Yu E, et al
    Association of Rare Variants in ARSA with Parkinson's Disease.
    Mov Disord. 2023 Jun 28. doi: 10.1002/mds.29521.
    >> Share

  502. PAL G, Cook L, Schulze J, Verbrugge J, et al
    Genetic Testing in Parkinson's Disease.
    Mov Disord. 2023 Jun 27. doi: 10.1002/mds.29500.
    >> Share

  503. DIRKX MF, Shine JM, Helmich RC
    Integrative Brain States Facilitate the Expression of Parkinson's Tremor.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29506.
    >> Share

  504. VENUTO CS, Smith G, Herbst K, Zielinski R, et al
    Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29519.
    >> Share

  505. LIN CP, Knoop LEJ, Frigerio I, Bol JGJM, et al
    Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
    Mov Disord. 2023 Jun 22. doi: 10.1002/mds.29510.
    >> Share

  506. SICILIANO M, De Micco R, Russo AG, Esposito F, et al
    Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29502.
    >> Share

  507. HAMEDANI AG, Auinger P, Willis AW, Safarpour D, et al
    Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29507.
    >> Share

  508. SIMONET C, Mahlknecht P, Marini K, Seppi K, et al
    The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29496.
    >> Share

  509. FLORES-TORRES MH, Bjornevik K, Hung AY, Healy BC, et al
    Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease.
    Mov Disord. 2023 Jun 14. doi: 10.1002/mds.29503.
    >> Share

  510. YASSINE S, Gschwandtner U, Auffret M, Duprez J, et al
    Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29451.
    >> Share

  511. SAUNDERS-PULLMAN R, Raymond D, Ortega RA, Shalash A, et al
    International Genetic Testing and Counseling Practices for Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29442.
    >> Share

  512. SCOTT GD, Neilson LE, Woltjer R, Quinn JF, et al
    Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29457.
    >> Share

  513. GILES DORAN C, Wilson F, Goulding SR, Mazzocchi M, et al
    Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
    Mov Disord. 2023;38:1115-1116.
    >> Share

  514. WHONE A
    Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
    Mov Disord. 2023;38:1117-1118.
    >> Share

  515. PAL GD, David FJ, Shils JL, Munoz MJ, et al
    Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2023;38:1113-1114.
    >> Share

  516. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    Reply to: "Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease".
    Mov Disord. 2023;38:1114.
    >> Share

  517. NEUMANN WJ, Gilron R, Little S, Tinkhauser G, et al
    Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation.
    Mov Disord. 2023;38:937-948.
    >> Share

  518. MARTINO D, Karnik V, Bhidayasiri R, Hall DA, et al
    Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
    Mov Disord. 2023;38:1008-1026.
    >> Share

  519. SCHIDLITZKI A, Stanojlovic M, Fournier C, Kaufer C, et al
    Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein.
    Mov Disord. 2023;38:1044-1055.
    >> Share

  520. STEFANI A, Serradell M, Holzknecht E, Gaig C, et al
    Low Specificity of Rapid Eye Movement Sleep Behavior Disorder Questionnaires: Need for Better Screening Methods.
    Mov Disord. 2023;38:1000-1007.
    >> Share

  521. UEDA J, Uemura N, Ishimoto T, Taguchi T, et al
    Ca(2+) -Calmodulin-Calcineurin Signaling Modulates alpha-Synuclein Transmission.
    Mov Disord. 2023;38:1056-1067.
    >> Share

  522. PEREZ-CARBONELL L, Simonet C, Chohan H, Gill A, et al
    The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
    Mov Disord. 2023;38:1089-1093.
    >> Share

  523. KUZKINA A, Panzer C, Seger A, Schmitt D, et al
    Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy.
    Mov Disord. 2023;38:1077-1082.
    >> Share

    May 2023
  524. PAYNE T, Appleby M, Buckley E, van Gelder LMA, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
    Mov Disord. 2023 May 29. doi: 10.1002/mds.29450.
    >> Share

  525. GEORGIADES MJ, Shine JM, Gilat M, McMaster J, et al
    Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease.
    Mov Disord. 2023 May 25. doi: 10.1002/mds.29455.
    >> Share

  526. DOMEN CH, Sillau S, Liu Y, Adkins M, et al
    Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Delta9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29447.
    >> Share

  527. HUTTUNEN HJ, Booms S, Sjogren M, Kerstens V, et al
    Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29426.
    >> Share

  528. KROSCHE M, Kannenberg S, Butz M, Hartmann CJ, et al
    Slowing of Frontal beta Oscillations in Atypical Parkinsonism.
    Mov Disord. 2023 May 20. doi: 10.1002/mds.29378.
    >> Share

  529. DEN HEIJER JM, Kruithof AC, Moerland M, Walker M, et al
    A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
    Mov Disord. 2023 May 17. doi: 10.1002/mds.29346.
    >> Share

  530. RAFEE S, Fearon C
    Palmitoylation: A New Therapeutic Target for Parkinson's Disease?
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29418.
    >> Share

  531. MAMARIL-DAVIS JC, Gelb AW, Larson PS
    Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis.
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29406.
    >> Share

  532. SCHIRINZI T, Maftei D, Grillo P, Bovenzi R, et al
    Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29433.
    >> Share

  533. BROWN GC, Camacho M, Williams-Gray CH
    The Endotoxin Hypothesis of Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29432.
    >> Share

  534. RYMAN SG, Shaff N, Dodd A, Nitschke S, et al
    Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29429.
    >> Share

  535. OUTEIRO TF, Alcalay RN, Antonini A, Attems J, et al
    Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29419.
    >> Share

  536. KOROS C, Brockmann K, Simitsi AM, Bougea A, et al
    Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29399.
    >> Share

  537. SENKEVICH K, Alipour P, Chernyavskaya E, Yu E, et al
    Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29424.
    >> Share

  538. VALENTIJN PP, Eggers C, Bloem BR, Grimes D, et al
    Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29413.
    >> Share

  539. NG J, Barral S, Waddington SN, Kurian MA, et al
    Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29416.
    >> Share

  540. JOST ST, Kaldenbach MA, Antonini A, Martinez-Martin P, et al
    Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29410.
    >> Share

  541. AVERNA A, Debove I, Nowacki A, Peterman K, et al
    Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation.
    Mov Disord. 2023;38:818-830.
    >> Share

  542. LOFREDI R, Scheller U, Mindermann A, Feldmann LK, et al
    Pallidal Beta Activity Is Linked to Stimulation-Induced Slowness in Dystonia.
    Mov Disord. 2023;38:894-899.
    >> Share

  543. ZHANG D, Shi Y, Yao J, Zhou L, et al
    Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Mov Disord. 2023;38:764-773.
    >> Share

    April 2023
  544. MESTRE TA, McDermott MP, Lobo R, Ferreira JJ, et al
    The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mov Disord. 2023 Apr 24. doi: 10.1002/mds.29414.
    >> Share

  545. GEROIN C, Artusi CA, Nonnekes J, Aquino C, et al
    Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
    Mov Disord. 2023 Apr 20. doi: 10.1002/mds.29377.
    >> Share

  546. LI C, Lin J, Jiang Q, Yang T, et al
    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29411.
    >> Share

  547. OH YS, Kim JS, Lyoo CH, Kim H, et al
    Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29402.
    >> Share

  548. BELOVA E, Semenova U, Gamaleya A, Tomskiy A, et al
    Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Apr 6. doi: 10.1002/mds.29393.
    >> Share

  549. MULLER T, Kuhn W
    Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
    Mov Disord. 2023;38:710-711.
    >> Share

  550. THALER A, Mirelman A, Alcalay RN
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:713-714.
    >> Share

  551. YANG X, Xiao Q
    Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
    Mov Disord. 2023;38:711.
    >> Share

  552. LANG AE
    Targeting alpha-Synuclein: A Further Viewpoint.
    Mov Disord. 2023;38:715-716.
    >> Share

  553. POSTUMA RB, Lang AE
    The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better.
    Mov Disord. 2023;38:515-517.
    >> Share

  554. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:714-715.
    >> Share

  555. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: "Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort".
    Mov Disord. 2023;38:709-710.
    >> Share

  556. KRESOJEVIC N, Markovic V, Dobricic V, Stankovic I, et al
    Reply to: "Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism".
    Mov Disord. 2023;38:712-713.
    >> Share

  557. LI C, Lin J, Jiang Q, Yang T, et al
    Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2023;38:708-709.
    >> Share

  558. BOLOGNA M, Espay AJ, Fasano A, Paparella G, et al
    Redefining Bradykinesia.
    Mov Disord. 2023;38:551-557.
    >> Share

  559. HUANG SY, Chen SF, Cui M, Zhao M, et al
    Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:676-682.
    >> Share

    March 2023
  560. BORSCHE M, Pratuseviciute N, Schaake S, Hinrichs F, et al
    The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
    Mov Disord. 2023 Mar 27. doi: 10.1002/mds.29385.
    >> Share

  561. ZENG R, Wang J, Zheng C, Jiang R, et al
    Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders.
    Mov Disord. 2023 Mar 23. doi: 10.1002/mds.29386.
    >> Share

  562. ZHOU G, Ren J, Rong D, Zhou H, et al
    Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2023 Mar 22. doi: 10.1002/mds.29366.
    >> Share

  563. MESTRE TA, Schlossmacher MG
    Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?
    Mov Disord. 2023 Mar 21. doi: 10.1002/mds.29382.
    >> Share

  564. FLORES-TORRES MH, Christine CW, Bjornevik K, Molsberry SA, et al
    Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men.
    Mov Disord. 2023 Mar 20. doi: 10.1002/mds.29383.
    >> Share

  565. DEN HEIJER JM, Cullen VC, Pereira DR, Yavuz Y, et al
    A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
    Mov Disord. 2023 Mar 14. doi: 10.1002/mds.29360.
    >> Share

  566. MUNOZ-DELGADO L, Labrador-Espinosa MA, Macias-Garcia D, Jesus S, et al
    Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
    Mov Disord. 2023 Mar 13. doi: 10.1002/mds.29369.
    >> Share

  567. KAMATH T, Macosko EZ
    Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics.
    Mov Disord. 2023 Mar 7. doi: 10.1002/mds.29374.
    >> Share

  568. DORSEY ER, Ray A
    Paraquat, Parkinson's Disease, and Agnotology.
    Mov Disord. 2023 Mar 6. doi: 10.1002/mds.29371.
    >> Share

  569. BLAUWENDRAAT C, Tayebi N, Woo EG, Lopez G, et al
    Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Mov Disord. 2023 Mar 3. doi: 10.1002/mds.29342.
    >> Share

  570. MARSILI L, Duque KR, Gregor N, Abdelghany E, et al
    Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases.
    Mov Disord. 2023;38:496-501.
    >> Share

  571. JENSEN PH, Schlossmacher MG, Stefanis L
    Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein.
    Mov Disord. 2023;38:378-384.
    >> Share

  572. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
    Mov Disord. 2023;38:444-452.
    >> Share

  573. WANG EW, Brown GL, Lewis MM, Jellen LC, et al
    Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
    Mov Disord. 2023;38:464-473.
    >> Share

  574. TAN C, Nawaz H, Lageman SK, Cloud LJ, et al
    Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:474-479.
    >> Share

  575. WIEST C, Morgante F, Torrecillos F, Pogosyan A, et al
    Subthalamic Nucleus Stimulation-Induced Local Field Potential Changes in Dystonia.
    Mov Disord. 2023;38:423-434.
    >> Share

  576. ROSSI M, Hamed M, Rodriguez-Antiguedad J, Cornejo-Olivas M, et al
    Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.
    Mov Disord. 2023;38:368-377.
    >> Share

    February 2023
  577. YACOUBIAN TA, Fang YD, Gerstenecker A, Amara A, et al
    Brain and Systemic Inflammation in De Novo Parkinson's Disease.
    Mov Disord. 2023 Feb 28. doi: 10.1002/mds.29363.
    >> Share

  578. EMMI A, Sandre M, Russo FP, Tombesi G, et al
    Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
    Mov Disord. 2023 Feb 27. doi: 10.1002/mds.29358.
    >> Share

  579. SCIACCA G, Mostile G, Disilvestro I, Donzuso G, et al
    Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Mov Disord. 2023 Feb 25. doi: 10.1002/mds.29344.
    >> Share

  580. GOETZ CG, Choi D, Guo Y, Stebbins GT, et al
    It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
    Mov Disord. 2023;38:342-347.
    >> Share

  581. GARRIDO A, Fairfoul G, Tolosa E, Marti MJ, et al
    Brain and Cerebrospinal Fluid alpha-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Mov Disord. 2023;38:333-338.
    >> Share

  582. OLSEN AL, Clemens SG, Feany MB
    Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
    Mov Disord. 2023;38:244-255.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016